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ABSTRACT 
 	
Excitation-contraction coupling (ECC) is the physiological mechanism whereby an 
electrical signal detected by the dihydropyridine receptor, is translated into an 
increase in [Ca2+], by activating ryanodine receptors. Mutations in RYR1, the gene 
encoding the ryanodine receptor 1, are the underlying cause of several congenital 
myopathies including Central core disease, Multiminicore disease, some forms of 
Centronuclear myopathy and Congenital fiber type disproportion. Patients with 
recessive but not dominant RYR1 mutations show a significant reduction of ryanodine 
receptor protein in muscle biopsies as well as ophthalmoplegia or involvement of the 
extraocular muscles (EOM). This specific involvement indicates that this group of 
muscles may express different proteins involved in excitation-contraction coupling 
compared to limb muscles. The focus of this thesis is the characterization of the 
excitation-contraction coupling toolkit of human EOM. The main goal was to identify 
differences or similarities with other skeletal muscles in the context of the previously 
mentioned diseases which affect skeletal muscles. My results indicate that the 
transcripts of the main genes involved in skeletal excitation-contraction coupling are 
downregulated, while at the same time, we report increased expression of the 
ryanodine receptor 3, cardiac calsequestrin and alfa 1 subunit of the cardiac 
dihydropiridine receptor. In addition, the finding of increase in excitation-coupled 
calcium entry in the EOM compared to leg muscles (LM) completes the picture of the 
EOM muscles as a specific muscle group with a unique mode of calcium handling 
and their selective involvement in neuromuscular disorders. 	
Facial weakness and ptosis have also been described in patients with mutations in 
RYR1. Having this in mind, we were interested in investigating the relation between 
the facial muscle orbicularis oculi (OO), EOM and LM and the excitation-contraction 
coupling toolkit in human biopsies and myotubes derived from individuals which do 
not have any known neuromuscular disorder. According to our results, OO show 
more similarities to leg muscles than to EOM. In addition, we found high expression 
levels of dystrophin and utrophin and this is significant from the perspective of 
Duchenne muscular dystrophy (DMD). In fact in this condition EOM are spared from 
pathology and the same is true in mdx (dystrophin deficient) mouse models. In mdx 
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mice it is believed that utrophin compensates for the lack of dystrophin. Our findings 
that UTRN is expressed at higher level in OO compared to LM in normal conditions 
strongly support this theory of a compensatory effect by utrophin when dystrophin is 
missing. 	
Further investigations in my thesis focus on two isoforms of the ryanodine receptor, 
namely RyR1 and RyR3. Ryanodine receptor 1 plays a crucial role in the process of 
excitation-contraction coupling in skeletal muscle. According to our study on normal 
human EOM, the expression of this receptor is decreased compared to its expression 
levels in human leg muscles, however the expression level of RyR3 is significantly 
increased. Because of these latter results, we reasoned that the reported behavioral 
impairment reported in RYR3 KO mice, may actually be due to alterations of EOM 
function. Our preliminary data show that in fact RYR3 KO mice exhibit visual 
impairment as measured using their optokinetic reflex. We are currently investigating 
the role of RyR3 in EOM calcium homeostasis.  	
Taken all together, this thesis shows that different involvement of EOM and OO in 
neuromuscular disorders is due to their different excitation contraction coupling 
toolkit component. Furthermore, EOMs exhibit characteristics that deserve further 
attention as further investigations may lead to the discovery of protective mechanisms 
in neuromuscular disorders with potential therapeutic benefit.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Craniofacial muscles 	
More than 10% of the total number of muscles in the human body are found in the 
craniofacial region. The craniofacial muscles are involved in a number of crucial non-
locomotor activities, and are critical for the most basic functions of life, including 
vision, taste, chewing and food manipulation, swallowing, respiration, speech, as well 
as regulating facial expression and controlling facial aperture patency. The biology of 
these small skeletal muscles is relatively unexplored. According to their 
developmental origin, they can be divided into extraocular muscles, branchiomeric 
muscles (facial, masticatory, pharyngeal and laryngeal muscles) and tongue muscles 
[1]. Their unique embryonic development and the genes that control it together with 
characteristic features that separate them from the skeletal muscle stereotype have 
started to be explored only recently	[2].  
 
Limb and trunk skeletal muscles are derived from the segmented paraxial mesoderm 
known as somites [2] while the origin of facial muscles is different and they do not 
follow the progression from mesoderm to segmented somites. The cranial mesoderm 
from which craniofacial muscles derive seems to be characterized more by molecular 
factors than for example, by anatomical ones [3], however, there is little information 
on the formation of facial muscles. The craniofacial muscles are highly heterogeneous 
as far as structure, function, anatomy and development are concerned. There are 
around 60 muscles in the head of vertebrates namely, those surrounding the eye - 
extraocular muscles (EOM) (derived from prechordal and paraxial mesoderm), those 
involved in mastication (derived from pharyngeal arch 1) and facial expression  
(derived from pharyngeal arch 2). The muscles of the 3rd pharyngeal arch (also known 
as branchial arch) control the larynx and pharynx. A number of head muscles 
(including the hypobranchial, tongue, posterior arch muscles) develop from the 
somites (Fig.1) [4]. 
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Figure 1: Development of skeletal muscles. Skeletal muscles and satellite cells in trunk 
and limb derive from somites  (paraxial mesoderm). Pharyngeal arch (PA) muscles and their 
associated satellite cells derive from both cranial paraxial mesoderm and splanchnic 
mesoderm sources. Extraocular muscles derive from prechordal and paraxial mesoderm 
(somitomeres) [4].  
 
1.1.1 Human extraocular muscles  
 
Understanding the biology of skeletal muscles, does not necessarily mean 
understanding and knowing the physiology of extraocular muscles. They are among 
the fastest and most fatigue resistant muscles, but at the same time the presence of the 
slow, non-twitch muscles and some cardiac or embryonic skeletal muscle 
characteristics gives them a special place when it comes to classification [5, 6]. EOM 
are highly specialized muscles with six fiber types, high-frequency pattern of 
neuromuscular innervation as well as the singly and multiply innervated fibers which 
sets them in a distinctive group of muscles compared to the other skeletal muscles [7]. 
At early stages the development of extraocular muscles is dependent on the 
expression level of the transcription factor Pitx2. If the expression of Pitx2 is low, the 
formation of the oblique muscles does not occur, and the rectus muscles that develop 
are smaller. In case of Pitx2 absence the extraocular muscles do not develop at all [8, 
9]. Extraocular muscles derive from prechordal and paraxial mesoderm (somitomeres) 
[4]. 
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There are the six extraocular muscles, which act to turn or rotate an eye about its 
vertical, horizontal, and antero-posterior axes: superior rectus, inferior rectus, medial 
rectus, lateral rectus, superior oblique and inferior oblique (Fig. 2).  	
                       	
 
Figure 2: Human extraocular muscles. 
(http://www.allaboutvision.com/conditions/strabismus-surgery.htm) 
 
 
The histological structure of eye muscles differs in many aspects from that of other 
striated muscles. Extraocular muscles contain fibers of varying diameters and in 
general they are the finest fibers found in any striated muscle. They vary in diameter 
from 9 µm to 17 µm, with fibers as fine as 3 µm, but these muscles also contain 
coarse fibers up to 50 µm in width. As far as the literature goes there is no consensus 
as to whether each EOM fiber runs the entire length of the EOM or not. In general if 
each muscle would run the entire length, one would expect to find the same number 
of fibers in sections taken from the anterior, middle, or posterior portion of each 
EOM. But instead, it has been reported that the number of fibers in the central region 
of the muscle is higher than in proximal or distal areas [10, 11]. 
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In extraocular muscles two layers can be distinguished: the orbital and global (Fig. 3) 
[12]. The orbital layer faces the orbital wall while the global layer faces the eyeball 
and is in part enclosed by the orbital layer. The orbital layer contains small-diameter 
fibers with many mitochondria and a dense vascular network. The global layer 
contains larger-diameter fibers with a variable content of mitochondria and fewer 
vessels.  
	
Figure 3: Cross section of (a) human and (b) rat ocular medial rectus muscle. 
Histochemical staining for succinate dehydrogenase (SDH) exhibits higher oxidative activity 
in the thinner orbital layer than in the thicker global layer. Human medial rectus muscle is 
much larger with a broad intermediate layer and a lot of connective tissue separating muscle 
fascicles. Scale bar 50µm [13].	 	
In human EOM a third layer has been described and named marginal zone, located 
outside of the orbital layer, with fibers larger than the ones from the orbital layer and 
with a higher number of the multiply innervated fibers. It covers the whole length of 
the muscle except the very proximal and distal regions [10].  
The EOM function could not be assigned to any particular layer. Predicting the 
function of any muscle without first establishing the mechanical connections between 
the fibers would be difficult and challenging. Elastic tissue is unusually abundant in 
extraocular muscles of adults and the elastic fibers are thick and arranged parallel to 
the muscle fibers. These longitudinal fibers are interconnected by transverse elastic 
fibers that form a very dense network around the muscle fibers. Recent anatomic 
studies have demonstrated that each rectus EOM passes through a pulley consisting of 
a surrounding ring or sleeve of collagen, located near the globe equator in Tenon’s 
capsule (Fig. 4). Pulleys are connected to the orbital wall, adjacent EOMs, and 
	14		
equatorial Tenon’s capsule by bands containing collagen, elastin, and smooth muscles 
[14, 15]. Spindles are located in the peripheral layers of small diameter fibers and near 
their tendon. In general there are around 50 spindles in each EOM.  
 
Figure 4: A pulley, that is supported by the orbital layer of the muscle guides the global 
layer that inserts in the globe. (http://www.efelder.de/eye_muscle_morphology.html) 
 
 
Myosin Heavy Chain expression in human EOM 
The highly specialized function of EOMs, that is to move the eyeball, is reflected in 
the specific Myosin Heavy Chain (MyHC) content and the complexity of fiber types. 
The MyHC expression pattern in adult EOM is different than that in adult skeletal 
muscle; in fact in single EOM fibers, developmental MyHC isoforms (neonatal and 
embryonic), are co-expressed together with adult MyHC isoforms, while normal adult 
skeletal muscle fibers only express adult MyHC isoforms [16-18]. The EOM specific 
MyHC13 isoform is also present in EOM [16] but additionally variations in MyHC 
isoform expression along single muscle fibers have been described [19]. Adult rabbit 
EOM also contain the cardiac MyHC isoforms [20]. 
In a study on the MyHC composition in human EOM, six isoforms were detected: 
MyHCemb/IIx, MyHCIIa, MyHCeom, MyHCI, and 2 unidentified forms. MyHCIIb 
was not detected. In the same study it was also shown that MyHC isoforms have a 
different pattern of expression in the human superior oblique muscle compared to the 
rectus muscles and inferior oblique muscles [21].  
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EOM fiber types 
Human skeletal muscle fibers are usually divided into three major types based on their 
physiological, biochemical and histochemical characteristics: 1) slow twitch, fatigue 
resistant (type I fibers), 2) fast-twitch, fatigue resistant (type IIA fibers) and 3) fast-
twitch fatigable (type IIB fibers - based on ATPase staining, IIX based on MyHC 
composition) [22]. EOM fiber classification can differ significantly based on the 
criteria taken for the fiber type characterization. The initial classification was based 
on the histological features and they were called “Feldenstruktur” or 
“Fibrilenstruktur” [23]. The slow fibers of the Felderstruktur type were described as 
clumped together in a more or less afibrillar appearing mass of myofilaments with 
large, partially fused fibers in sparse  sarcoplasm with poorly developed sarcoplasmic 
reticulum. The Fibrillenstruktur type of the fast fiber system were characterized 
anatomically by small, well defined fibers, each surrounded by abundant sarcoplasm 
and having an even, punctate appearance when observed under the light microscope. 
Classification in “coarse”, “granular” and “fine” came with the characterization of the 
amount and distribution of mitochondria [24]. This was followed by a more 
comprehensive description of rat EOM fiber types which included, location, diameter, 
innervation pattern, histochemical features and ultrastructure. Based on these criteria, 
six fiber types could be identified [25]. Later studies in different mammals confirmed 
the presence of the six different fiber types in EOM. 
In human EOM fiber type classification, mitochondrial content was used to 
distinguish the different fiber types [26]. Studies based on ATPase staining together 
with the glycolytic and oxidative enzyme activity and MyHC isoform expression 
confirmed the higher complexity and fiber type diversity in EOM [27].  
It is now generally agreed that in humans and higher mammals there are six fiber 
types in the EOMs and these can be classified on the basis of their location, 
innervation and color into: 1) orbital multiply innervated, 2) orbital singly innervated, 
3) global multiply innervated, 4) global red singly innervated, 5) global intermediate 
singly innervated and 6) global pale singly innervated fibers	 [12]. None of the 
previously mentioned methods independently covers the full extent of differences 
present in EOM fibers [10]. 
 
	16		
Innervation of EOM 
 
EOMs are innervated by lower motor neurons that form three cranial nerves: the 
abducens, the trochlear, and the oculomotor [28]. Compared to other skeletal muscles 
they are highly innervated and exist as both singly innervated fibers (SIFs) and 
multiply innervated fibers (MIFs), whereas trunk and limb skeletal muscles contain 
exclusively  singly innervated fibers [29]. 	
The motor neurons are very thick, due to the large number of fibers they contain. The 
ratio of nerve fibers to muscle fibers is nearly 1:12 in extraocular muscles, whereas in 
skeletal muscles it may be as high as 1:125. The abundance of nerve fibers has led to 
the conclusion that the all-or-none law could apply to eye muscles. According to this 
general principle, individual muscle fibers always respond with a maximum 
contraction to every stimulus that exceeds the threshold potential, otherwise there is 
no response. The amount of contraction of a muscle depends on the number of fibers 
taking part in a contraction [30]. 
 
Physiology of EOM 	
The physiological and pharmacological properties of extraocular muscles correspond 
to many unusual histological features. In an electromyographic study it was shown 
that responses of human extraocular muscles are considerably lower in amplitude (20 
to 150 µV), of much shorter duration (1 and 2 ms), and much higher in frequency (up 
to 150 cps (contractions per second)), than those of peripheral skeletal muscles, in 
which the amplitude is 100 to 3000 µV, the duration, 5 to 10 ms and the frequency 
only up to 50 cps [30]. 
Extraocular muscles contract much more quickly than other voluntary muscles. As a 
measure of comparison, contraction times on cat muscles were: soleus muscle, 100 
ms; gastrocnemius muscle, 40 ms; and medial rectus muscle, 8 ms.	[31, 32]. The great 
speed of contraction of extraocular muscles is in keeping with the requirements of 
saccadic eye movements and with what is known of the structure and innervation of 
extraocular muscles.  
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Since the discovery that a dual motor system of slow and fast fibers exists in 
extraocular muscles, experiments have shown that acetylcholine, choline, and nicotine 
cause slow and tonic contraction of slow fibers, whereas fast fibers respond with a 
fast twitch. The response of extraocular muscles to neuromuscular blocking agents is 
of clinical interest, since these drugs are often used during general anesthesia [30].  
 
 
1.1.2 Orbicularis oculi muscles (OO) 
 
 
Orbicularis oculi (OO), together with the tarsal plate form the core of the eyelid. 
These are muscles important for facial expression and are innervated by the facial 
nerve (VII) [33]. OO are located directly under the surface of the skin around the 
eyes. Their function is to close the eyelid and to assist in passing and draining tears 
through the tear draining system. They are composed of three portions: the orbital 
portion, the palpebral portion and the lacrimal portion (Fig. 5). The orbital portion is 
involved in closing the eyelids firmly and is controlled by voluntary action. Coarse 
fibers surround the entire orbit. It has two origins: the frontal bone and the maxilla. 
The insertion circles around the orbit and it contracts to tightly close the eyes. The 
palpebral portion closes the eyelids gently as part of the involuntary or blinking 
reflex. This portion has three parts: the pretarsal, preseptal and ciliary part. It is made 
up of fine fibers and originates from the medial palpebral ligament and inserts into the 
zygomatic bone, specifically at the lateral palpebral ligament. The lacrimal portion 
compresses the lacrimal sac, which receives tears from the lacrimal ducts and 
transfers them into the nasolacrimal duct. Its origin is the lacrimal bone and its 
insertion is the lateral palpebral raphe. It has its own ciliary bundle [34]. 
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Figure 5: The three anatomical portions of human orbicularis oculi muscle [35]. 
 
The anatomy of the orbicularis oculi muscle is important in treating a number of 
conditions that require corrective eyelid surgery. It is also important in the physiology 
of blinking, corneal wetting, and lacrimal excretion through the lacrimal pump.The 
fibers in orbicularis oculi muscles have the smallest diameter of any skeletal muscle. 
There are differences in fiber cross-section and fiber type composition between 
different portions of the muscle. The pretarsal region has the smallest fiber cross-
sectional areas and this region is composed almost entirely of type II fibers. The 
number of type I fibers increases when moving away from the eyelid margin towards 
the periphery, but the muscle in general is 80-90% composed of type II fibers [33].  
 
The OO differ from both limb and extraocular muscles (EOM) in their histology and 
histochemistry. In OO there is a predominance of type IIB fibers, the fast fibers which 
are not able to sustain contraction for long periods of time due to fatigue and are 
ideally suited for blinking. Sustained squeezing of the eyelids can occur due to type 
IIA fibers which are fast but fatigue resistant. During sleep the OO are at rest, and the 
lid position is determined by the equilibrium between the state of relaxation of the 
levator muscles and OO [36].  
 
The OO differ from some other facial muscles with regard to the ratio of type II 
muscle fiber subtypes. It was reported that type IIB fibers are present in the levator 
labii and OO. Type II fibers are more numerous in each of the facial muscles than in 
limb muscles [36].  
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Normal OO possess some features which, when present in limb or trunk muscles, 
would be considered consistent with a chronic myopathy or dystrophy. These include 
marked fiber size variation, rounded fiber shape, structural alterations such as 
lobulation and irregular coarseness of stainable sarcoplasmic network, absence of 
checkerboard pattern of fiber-type distribution, and an increase in endomysial and 
perimysial connective tissue. Although the OO do not appear to possess many of the 
characteristics of EOM, they are similar to them and to other facial muscles and can 
be placed somewhere between them with respect to	 histologic and histochemical 
parameters [36]. 
 
1.2 Excitation-contraction coupling (ECC) 
 
1.2.1 ECC in skeletal muscle 
Excitation-contraction coupling is the mechanism which involves a specific sequence 
of events starting from initiation and propagation of the action potential (AP) along 
the plasma membrane (sarcolemma), radial spreading of the potential along the 
transverse T-tubule system, DHPR (L-type Ca2+ channel)-mediated detection of 
changes in membrane potential, allosteric interaction of DHPR with RyR, release of 
Ca2+ from the SR and transient increase in cytoplasm Ca2+ concentration, transient 
activation of the cytoplasmic Ca2+ buffering system and contractile machinery, 
followed by a decrease of the cytoplasmic Ca2+ levels by the reuptake by SR through 
sarcoendoplasmatic reticulum Ca2+ transport ATPase (SERCA)	and to a lesser extent 
by its transport by the Na+/Ca2+ exchanger (NCX) and plasma membrane Ca2+ATPase 
(PMCA) [37-39].  
The release of divalent ions from the SR requires the expression of both the skeletal 
muscle L-type Ca2+ channel DHPR and the RyR1 since depolarization-induced Ca2+ 
entry is absent in myotubes lacking either the DHPR α1S subunit (dysgenic) or RyR1 
(dyspedic), respectively [40]. Skeletal ECC is practically exclusive for RyR1, since 
RyR2 and RyR3 are not able to recover the skeletal type of ECC when expressed in 
RyR1 deficient skeletal muscle cells [41].  
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T-tubules are invaginations of the plasma membrane that transversely expand into the 
muscle fiber allowing  membrane depolarization to reach deep into the fiber to form 
the triad, i.e a region, where one T-tubule is surrounded by two terminal cisternae of 
the SR with their so called junctional regions [42, 43]. In the junctional region RyR1 
face DHPR receptors located on the membrane of the T-tubule forming tetrads (Fig. 6 
and 7) [44, 45]. 
 
Figure 6: T-tubule DHPR and RyR localization. (https://www.premedhq.com/t-
tubule-system) 
 
Many proteins are engaged in the process of the ECC among them, calsequestrin, 
triadin, junctin, junctophilin, FKBP12, mitsugumin, sarcalumenin and JP45. 
Nevertheless RyR1s and DHPRs are considered the main players since in their 
absence no ECC occurs.  
The DHPR is the physiological regulator of the RyR1 during ECC, but it is by no 
means the only regulator of RyR1 channel activity. Like RyR2 channels present in the 
heart, in the absence of the DHPR, RyR1 channels can be activated by cytosolic Ca2+ 
via a process called Ca2+ induced Ca2+ release (CICR). This is important because 
more than half of the RyR1 channels are not coupled to DHPRs [46, 47] and it is 
generally believed that CICR acts to amplify the signal that is generated by the 
DHPR-RyR1 interaction. Interestingly, the presence of “coupled” and “uncoupled” 
RyR1 channels indicates that RyR1 function can be heterogeneous. The amount of 
uncoupled RyR1 channels is not the same in all skeletal muscles. Slow-twitch skeletal 
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muscles may have three or more uncoupled RyR1 channels for each DHPR-linked 
RyR1 channel [46, 47]. Slow-twitch muscles have a slower rate of ECC and the 
number of uncoupled RyR1 may be partially responsible for this and in line with the 
fact that they have a more pronounced CICR  [48, 49]. 
 
 
 
Figure 7: Structure of Calcium Release Units in adult skeletal muscle fibers. In 
adult skeletal muscle, junctions are mostly triads: two SR elements coupled to a central T-
tubule. (A) A triad from the toadfish swim bladder muscle in thin section EM: the 
cytoplasmic domains of RyRs, or feet, and calsequestrin are well visible. (B) A tri-
dimensional reconstruction of a skeletal muscle triad showing the ultrastructural localization 
of RyRs, DHPRs, Calsequestrin, Triadin, Junctin, and Ca2+/Mg2+ ATPases. The DHPRs are 
intramembrane proteins that are not visible in thin section EM but can be visualized by freeze 
fracture replicas of T tubules (panel C). (C) DHPRs in skeletal muscle DHPRs form tetrads, 
group of four receptors (see enlarged detail), that are linked to subunit of alternate RyRs 
(smodels in B and E). (D) In sections parallel to the junctional plane, feet arrays are clearly 
visible (toadfish swimbladder muscle): feet touch each other close to the corner of the 
molecule (see enlarged detail). (E) Model that summarizes finding of panels C and D: RyRs 
form two (rarely three) rows and DHPRs form tetrads that are associated with alternate RyRs 
(RyRs in blue; DHPRs in purple; T-tubule in green). (EM courtesy of Clara Franzini-
Armstrong; 3D reconstruction of RyRs courtesy of T. Wagenknecht)	[50].  
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1.2.2 ECC in cardiac muscle 
In cardiac muscle, ECC is dependent on a phenomenon called calcium-induced 
calcium release (CICR). Calcium induced calcium release is, as its name indicates, a 
process whereby an increase in Ca2+ concentration at the cytoplasmic surface of the 
intracellular Ca2+ store induces a release of Ca2+. This process involves the 
conduction of calcium ions into the cell initiating further release of ions into the 
cytoplasm. This influx of Ca2+ occurs through the cardiac isoform of the alfa 1 
subunit of the DHPR	 [51] and is initiated by an action potential which triggers the 
Ca2+ release from the SR which leads to cardiac contraction. The initial trigger is 
generated by depolarization of the plasma membrane, which allows Ca2+ entry 
through the L-type Ca2+ channels located on the transverse T-tubules. This influx of 
Ca2+ initiates a large intracellular Ca2+ release from the SR via RyR2s, which elevates 
cytosolic Ca2+ concentrations from 100 nM during diastole to about 1 µM during 
systole, and this Ca2+ elevation activates cardiac contraction. 
 
There is about one DHPR for every 5 to 10 RyR2 channels in heart muscle and there 
is no finely defined alignment between these two proteins, as is the case in skeletal 
muscles (Fig. 8) [50, 52]. Long cardiac action potentials of about ~100ms give 
enough time for the DHPR to open and facilitate the influx of Ca2+ which will result 
in activation of the underlying RyR2 channels through the previously mentioned 
CICR mechanism. The fact that Ca2+ is the mediator of ECC in the heart makes signal 
transduction between cardiac DHPR and RyR2 much slower compared to that 
occurring between the skeletal isoforms of these proteins. This however, leaves more  
space for a higher level of regulation of DHPR-RyR2 interaction in cardiac muscle. 
[53, 54]. 
Procaine and tetracaine inhibit CICR and are used for investigating the physiology of 
this process. Ruthenium and high concentrations of ryanodine are inhibitors of RyR 
channels and also block CICR. In mature skeletal muscles CICR doesn`t play a 
primary role so its  exact role remains elusive.   
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Figure 8: Structure of calcium release units in cardiac myocytes. Junctions in 
cardiac muscle cells are usually in the form of dyads or peripheral coupling formed by SR and 
either a T-tubule or the sarcolemma. (A) DHPRs in cardiac junctions do not form tetrads, but 
they are randomly arranged in exterior membrane domains that face arrays of feet. This 
observation implicates that DHPRs are not directly linked to RyRs in the heart. (B) RyRs, 
pointed by the arrow, usually form large clusters instead of the two rows described for 
skeletal muscle junctions. (C) Tri-dimensional reconstruction of a cardiac muscle 
dyad/peripheral coupling showing the ultrastructural localization of RyRs, DHPRs, 
Calsequestrin, Triadin, and Junctin. Bar, 0.1 mm (3D reconstruction of RyRs courtesy of T. 
Wagenknecht)	[50]. 
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1.2.3 Components of ECC 
 
Ryanodine receptors (RyRs) 
As mentioned in the previous sections, Ca2+ is an essential component for the process 
of excitation-contraction coupling. The biggest store of Ca2+ in striated muscles is the 
sarcoplasmic reticulum (SR). The major channels located on the membrane of the SR 
which are responsible for Ca2+ release are ryanodine receptors (RyRs) while inositol 
1,4,5-triphosphate receptors (IP3Rs) for Ca2+ channels are located on the endoplasmic 
reticulum and are not involved in ECC [55, 56]. There are three isoforms of RyR 
receptors in vertebrates (RyR1, RyR2 and RyR3) which are encoded by three 
different genes and which vary in their tissue distribution. RyR1 is predominantly 
expressed in skeletal muscle and to a minor extent in some areas of the CNS and in 
some immune cells; RyR2 is present in the heart and in the cerebellum and RyR3 was 
first identified in the brain, but later identified in developing tissues, including 
developing skeletal muscle [57, 58]. The three isoforms share 65% sequence identity, 
the biggest difference being detected in areas called “divergent regions”; D1 (from 
residue 4254-4631 in RyR1), D2 (from residue 1342-1403) and D3 (from residue 
1872-1923)	 [58]. The name of the receptor comes from the alkaloid ryanodine 
isolated from the South American plant Ryania speciosa, which in nanomolar 
concentractions locks the channel in a subconductance state and in concentrations 
above 100µM induces inhibition of Ca2+ release [59-62]. 
Channel activity is modulated in a direct or indirect manner by dyhydropiridine 
receptors (DHPR) and a number of other proteins including protein kinase A, 
FKBP12 and FKBP12.6, calmodulin, S100, Ca2+/calmodulin dependent protein 
kinase II (CaMKII), calsequestrin (CSQ), triadin, junction, as well as by ions like 
Ca2+, Mg2+ [63-77]. 
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RyR1 
RyR1 is the biggest known ion channel with a homotetrameric structure, each subunit 
has an apparent molecular mass of ~565 kDa, and is made up of 5038 amino acids in 
human isoform ASI (-) and 5033 amino acids in isoform ASI (+). RYR1 was 
originally cloned and sequenced from skeletal muscle by Takeshima et al. and 
Zorzato et al. [78, 79]. The gene encoding human RyR1 is located on chromosome 
19q13.2. The C terminal region contains the transmembrane domains and ion 
conducting pore, while the major part of the protein is the N-terminal cytoplasmic 
region which contains the domain interacting with the DHPR as well as domains 
involved in channel modulation [80].  
Skeletal muscle is the tissue which is most enriched in RyR1 where it is located in the 
junctional region of the terminal SR [78, 79, 81] but other tissues  including smooth 
muscle cells, stomach, kidney, thymus, Purkinje cells, adrenal glands, ovaries, and 
testis, dendritic cells and B-lymphocytes also express this protein but in lower 
amounts [78, 82-88].  
The crystal structure of RyR is not yet fully resolved, but there are several cryo-EM 
studies which agree on the overall structure of the receptor (Fig. 9)	 [89-92]. The 
general structure can be presented as mushroom-like, with a big cap containing about 
80% of the total volume located in the cytoplasmic region, facing the transverse 
tubules and the stalk which goes through the membrane into the SR lumen. The 
cytoplasmic region is about 270×270×100Å and the trans-membrane region is 
120×120×60Å. The cytoplasmic cap is structured, contains many cavities and 
globular masses which may correspond to individual or groups of folded domains. 
The globular regions were numbered and are often called “subregions”	[93, 94]. Most 
cryo-EM investigations have been preformed on RyR1, there are several on RyR2 and 
RyR3 but to a lower resolution. In general, the overall structural shape is similar for 
all three isoforms	[95,	96].  
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Figure 9: Cryo-EM structures of RyR. Shown are isocontour maps for cryo-EM 
reconstructions of RyR at 9.6Å (EMDB accession number 1275) [97] . (A) and (B) top (from 
the cytosol facing the ER/SR membrane) and side views of the RyR. The numbers indicate 
subregions, a nomenclature that has been used extensively in literature.  
 
The number of the transmembrane helices is still under investigation, but the general 
consensus is that there are six or eight segments per subunit [98]. The inner helices 
create the pore-forming region. The purified protein can form a planar crystalline 
strucutre with a checkerboard pattern in the absence of any other protein [99]. 
Subregion 6 in the clamp region is responsible for the inter-protein interactions while 
the clamp region undergoes significant movement during opening and closing of the 
channel which can be also transmitted to the neighboring RyRs  [89, 100]. This 
feature could be partly responsible for the phenomenon of coupled gating, where 
opening of one channel can induce opening of the neighboring channels through 
physical interactions	[101].  
 
Lack of RYR1 in mice results in a lethal phenotype; knockout mice most likely die at 
birth because of breathing impairment, but they also exhibit skeletal abnormalities 
such as spinal curvature, arched vertebral column, thin limbs and a thick neck [102].  
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RyR2 	
RyR2 was first identified in cardiac muscle [84]. In humans, the gene encoding RYR2 
is located on chromosome 1q43 and spans 102 exons, RYR2 is also expressed at high 
levels in Purkinje cells of the cerebellum and cerebral cortex [103] and to lower levels 
in the stomach, smooth muscle cells, adrenal glands, ovaries, thymus and lungs [104] 
[83]. 	
RyR2 is the major SR Ca2+ release channel involved in cardiac excitation–contraction 
coupling, the process by which an electric depolarizing impulse is transduced into a 
cardiac contraction. The amount of released Ca2+ from the SR via RyR2 in great deal 
determines the Ca2+ transient amplitude, which correlates with the strength of systolic 
contraction [105]. The RyR2 channel consists of 4 pore-forming subunits that interact 
with numerous accessory proteins such as FKBP12.6, calmodulin, calsequestrin-2, 
junctin, triadin, and junctophilin-2. Each of these accessory proteins can regulate 
channel gating [106]. RyR2 is regulated at the post-translational level by S-
nitrosylation, oxidation, and protein phosphorylation [107]. 	
Mutations in RYR2 are associated with catecholaminergic polymorphic ventricular 
tachycardia (CPVT) and arrhythmogenic right ventricular dysplasia type 2 (ARVD2) 
[108, 109]. 
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RyR3 
 
In humans, the RYR3 gene is encoded by 103 exons and is located on chromosome 
15q13.3-14. RyR3 is expressed in hippocampal neurons, thalamus, Purkinje cells, 
corpus striatum, skeletal muscles with the highest expression in the diaphragm, 
smooth muscle cells of the coronary vasculature, lung, kidney, ileum, jejunum, 
spleen, stomach of mouse and aorta, uterus, ureter, urinary bladder, and esophagus of 
rabbit [58]. RyR3 is usually not the predominant RyR protein and it is often co-
expressed with RyR1 or RyR2 in different tissues. In adult diaphragm muscle, RyR3 
constitutes 1–4% of the total [3H]ryanodine binding sites and the rest is due to RyR1	
[110].  
 
In mice, the RyR3 protein can be detected in skeletal muscles from the 18th day of the 
embryonic stage up to 15 days postnatal. Later, during development the levels 
decrease and almost completely disappear [111]. In RYR3 KO mice, the isolated 
neonatal skeletal muscles show decreased tension development after stimulation with 
caffeine and contractile force after electrical stimulation. ECC is relatively normal in 
these mice compared to WT. Based on the available data, it seems that RyR3 have a 
role in both development and contraction of neonatal muscles [112], however, very 
little is known about its function. In fact, mice lacking RyR1 and RyR2 die early 
either at birth or during embryonic development [113, 114], while mice lacking RyR3 
live normal lives and show no significant changes in muscle function or reproduction. 
[112, 115]. In toadfish and frog skeletal muscles, RyR3 is localized on the 
parajunctional membranes, immediately adjacent to the junctional region from [116].   		
There are strong suggestions that the activation of RyR3 is indirect, since it is not 
activated by DHPR. It can be assumed that activation of RyR1 by the DHPR occurs 
first and then activation of RyR3 occurs by CICR which then contributes to the 
amplification of ECC induced Ca2+ release. Since parajunctional RyR do not seem to 
be in close proximity to junctional RyR, then one can exclude the functional 
interaction of parajunctional RyR3 and junctional RyR1. The most likely possibility is 
that RyR3 is activated by the Ca2+ wave coming from the activated  RyR1.  	
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Regulators of RyR: 
 
Ca2+ release via the RyR1 is finely controlled by number of proteins, small molecules 
and post-translational modifications that influence opening or closing of the channel 
(Fig. 10). 	
(i) FK506-binding proteins (FKBPs) 12 and 12.6 interact with all three 
RyR isoforms, more specifically FKPB12 co-purifies with RyR1 and FKBP12.6 with 
RyR2. FKBP12 is involved in stabilization of the closed state of the channels and 
prevents the occurrence of subconductance states [117]. Cryo-EM studies have shown 
that FKBPs bind to a site near subdomains 3, 5 and 9	[118, 119].  	
(ii) Calmodulin (CaM) is a 17kDa protein that binds to the cytoplasmic 
domain of the ryanodine receptor and affects its activity in a different manner 
depending on whether Ca2+ is bound or not. When it is in Ca2+ -free state or ApoCaM, 
it acts as a partial agonist, activating RyR1 and inhibiting RyR2, while at high Ca2+ 
concentrations in the Ca2+ -bound form known as CaCaM, it acts as an inhibitor of 
both RyR1 and RyR2 [73, 120]. ApoCaM and CaCaM bind to different RyR1 
domains, but some regions contained within residues 3614-3643 and 2937-3225 can 
act as binding sites for both states of calmodulin [121, 122]. Cryo-EM studies have 
identified the binding domains of apo-CaM and Ca2+/CaM on RyR1 [123]. According 
to this study the position of CaM on the 3D structure changes after Ca2+ binding.  	
(iii) Calsequestrin is Ca2+ buffering protein located in the lumen of the 
SR. Depending on the intraluminal Ca2+ levels, it can form oligomers and interact 
with junctin and triadin. It is believed that the calsequestrin-triadin-junctin complex 
can affect RyR activity, although the precise mechanism of action to achieve this 
effect has not been unraveled [124]. See the subsequent section for more information 
on calsequestrin.  	
(iv) Phospohorylation: Kinases such as PKA and CaMKII, as well as 
phosphatases such as PP1, PP2A and PDE4D3 target RyRs. Some of these enzymes 
are docked onto the RyRs through scaffolding proteins [125]. At least two residues in 
human RyRs are phosphorylated by PKA, namely Ser2843 in RyR1 and Ser2030, 
Ser2808 in RyR2.  
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(v) CaMKII is regulated by intracellular Ca2+ concentrations via CaM. It 
can phosphorylate Ser2843 in RyR1 and Ser2808 in RyR2 but also seems to have a 
unique phosphorylation site in RyR2 (Ser2814). CaMKII was found to increase the 
open probability and Ca2+ sensitivity of the channel and has also been shown to 
contribute to cardiac arrhythmia and contractile dysfunction	[126]. 
 
 
 
 
 
Figure 10: Binding partners and ligands of RyR.  (A) Schematic overview of the RyR 
and voltage-gated calcium channel (Cav), present in two different membranes, along with 
several binding partners in the cytoplasmic and luminal areas. 4-CmC, 4-chloro-m-cresol. (B) 
Locations of several protein-binding partners based on difference cryo-EM	[127]. 
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DHPR skeletal (Cav1.1) and cardiac (Cav1.2) isoforms  
 
Cav1.1 and Cav1.2 are the voltage gated calcium channels and together with the 
voltage-gated potassium and sodium channels, are members of the gene superfamily 
of transmembrane ion channel proteins. The α1 subunit having an approximate 
molecular mass of 190-250 KDa is the biggest subunit and acts as the voltage sensor 
and gate. The α1 subunit is organized in four homologous domains (I-IV) (Fig. 11) 
with six transmembrane segments in each domain (S1-S6). Channel regulation by 
second messengers, drugs and toxins occurs through known sites within the alpha 1 
subunit. The S4 segment is responsible for voltage sensing, while the pore loop 
between S5 and S6 in each domain determines ion selectivity and conductance.  
 
 
 	
Figure 11: Illustrated model of Cav1.1 subunit composition of channels isolated 
from skeletal muscle. Model fits to the current available data for Cav2 channels as well. 	
The Cav1 subfamily (Cav1.1 to Cav1.4) includes channels with 1S, 1C, 1D and 
1F which mediate L-type Ca2+ currents.	The genes encoding the different α1 subunits 
are not clustered on a single chromosome even for the close members of the family 
(Fig. 12) [128]. 	
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Figure 12: Cavα1 subunit gene tree. Full-length amino acid sequences for all 10 human 
Cavα1 genes were aligned using a branch and bound tree search with maximum parsimony 
(Genetic Computer Group, paupsearch and paupdisplay programs). Confidence values for 
each node were determined by bootstrap analysis. All unlabeled nodes represent 100% 
confidence	[129].  
 
 
It was shown that the cytoplasmic II-II loop of the skeletal DHPR α1 subunit is 
necessary for the functional DHPR-RyR1 interaction (Fig. 13). Other regions may 
play a role in the interaction but this area seems to be essential. The nature of the 
DHPR-RyR interaction is tissue specific, in skeletal muscle the physical interaction 
occurs through direct contact of the two proteins, while in cardiac muscle DHPR acts 
as a mediator of a small influx of Ca2+ which leads to the RyR2 channel activation	
[39]. 
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Figure 13: Interaction of RyR1 and RyR3 with skeletal DHPRs. (A) and (B) In 
dyspedic 1B5 cells (RyR1 -/-), DHPRs are clustered in correspondence of CRUs, but they are 
not grouped in tetrads as in normal skeletal muscle cells because of lack of RyR type 1 in the 
SR junctional domains. (C) and (D) DHPR tetrad arrangement is restored by transfection with 
cDNA encoding for RyR1. Dotting the center of tetrads in the array (C, bottom) results in an 
ordered pattern that is related to the arrays of feet in the SR. (E) and (F) RyR3 expression 
does not restore DHPR tetrad arrays suggesting that RyR3 in skeletal muscle cells does not 
interact directly with DHPRs as RyR1 does. Bar, 0.1 µm (3D reconstruction of RyRs courtesy 
of T. Wagenknecht)	[50]. 
 
 
The CaV1.2 gene (α1C) is expressed in a variety of cells including ventricular cardiac 
muscle, smooth muscle, pancreatic cells, fibroblasts, and neurons his channel opens as 
the membrane potential depolarizes beyond about −30 mV. CaV1.2 channels help 
define the shape of the action potential in cardiac and smooth muscle. These channels 
function primarily as calcium ion channels and, unlike CaV1.1 of skeletal muscle, 
calcium flow through CaV1.2 is an essential step in initiating the signaling cascade 
that leads to cardiac and smooth muscle contraction [39].  
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Sarcoendoplasmic reticulum Ca2+-ATPase SERCA  
 
SERCAs are members of the P-type ATPases; they are a made up of a single 
polypeptide of 110KDa and can be found in the ER and SR membrane. This group of 
ATPases is characterized by the transfer of the terminal phosphate from ATP to an 
aspartate residue in the catalytic domain inducing a reversible conformational change. 
SERCA uses the energy obtained from ATP hydrolysis to transport Ca2+ across the 
ER/SR membrane. For every hydrolyzed ATP molecule, two Ca2+ ions are 
transported. The activity of SERCA pumps is regulated by phospholamban and 
sarcolipin in a tissue specific manner. 
There are three genes encoding SERCA 1, 2 and 3. SERCA1 is found in fast-twitch 
skeletal muscle and has two isoforms SERCA1a adult and SERCA1b fetal. SERCA2a 
is found mostly in cardiac and slow-twitch skeletal muscles, while SERCA2b is 
expressed to low extent in all tissues. Recently a new isoform has been reported in 
cardiac muscle named SERCA2c. SERCA3 isoforms are found in non-muscle tissues 
mainly in hematopoietic cell lineages, platelets, epithelial cells, fibroblasts and 
endothelial cells. Low levels of this isoform have been detected in muscle tissue as 
well. The primary structure of SERCA isoforms is highly conserved. Thapsigargin 
inhibits all SERCA isoforms, and shows no effect on Na+/K+ or other ATPases [130]. 
Sarcalumenin  
 
In the longitudinal section of skeletal and cardiac sarcoplasmic reticulum two 
alternative splice products of the same gene known as 160 kDa sarcalumenin and 53 
kDa glycoprotein are present at low levels. Sarcalumenins are high capacity low 
affinity Ca2+ binding proteins while the 53 kDa glycoprotein does not bind Ca2+ as it 
lacks the NH2 terminus [131]. Sarcalumenin knockout (SARKO) mice exhibit mild 
cardiac dysfunction and show reduced SERCA activity and SERCA protein content 
[132], however  sarcalumenin deficiency leads to progressive heart failure in response 
to pressure overload [133]. 
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Triadin 
The single triadin gene TRDN gives rise to different isoforms formed by alternative 
splicing. In rat skeletal muscle three isoforms of triadin have been found, namely 
Trisk 95, Trisk 51 and Trisk 32. Trisk 95 and  Trisk 51 are expressed only in skeletal 
muscle where they localize to the triads and in association with RyR1 and CSQ1. 
Trisk 32 is the main cardiac isoform found in skeletal muscle it is expressed at low 
levels in the whole SR	 [134]. Triadin KO mice show cardiac and skeletal muscle 
impairments, with moderate muscle weakness and reduction in the amplitude of the 
Ca2+ transient. Isoproterenol induced arrhythmias were observed at the level of 
cardiac muscle [134].   
Junctin  
Junctin was first identified as a 26-kDa calsequestrin-binding protein in cardiac and 
skeletal muscle junctional SR membranes. It was originally proposed that junctin is 
responsible for anchoring calsequestrin to the SR membrane in proximity to the 
ryanodine receptor and indeed it was later shown that junctin binds to both 
calsequestrin and the ryanodine receptor as well as triadin. Results from our laboratoy 
provide strong support for a model in which a quaternary protein complex exists 
between junctin, triadin, calsequestrin, and the ryanodine receptor at the junctional SR 
membrane. This complex may be important for operation of Ca2+ release during 
excitation-contraction coupling in cardiac and skeletal muscle [135]. The close 
structural similarities between junctin and triadin suggest that both proteins have 
related functions. 
Mitsugumin 29  
According to its name mitsugumin29 is a 29kDa protein found in SR/ER membrane. 
It is localized in the triad junction of the skeletal muscle. It shares close to 45% 
homology with synaptophysin, a family of proteins with a role in secretion and 
release of the neurotransmitters. Mice lacking Mg29 showed reduced contractile 
force, altered structure of the triadic junction and are prone to fatigue indicating that 
this protein has a role in ECC [131, 136].  
	36		
Junctophilin-1  
There are at least three junctophillin isoforms encoded by distinct genes: 
junctophillin-1 is expressed in skeletal muscle, while junctophillin-2 and -3 are 
expressed in heart and brain. Junctophillin-1 a 72 kDa protein whose function is to 
physically link the T-tubules with the SR membrane via a probable phospholipid 
mediated interaction. KO mice for this gene die within 20h after birth [131].  
JP-45  
This protein is a 45 kDa transmembrane protein found in the skeletal muscle 
junctional face membrane, with highest expression levels during the second postnatal 
month. It was originally identified as a protein which is weakly phosphorylated by 
cAMP-dependent protein kinase and co-elutes with the DHPR from a heparin-agarose 
column [137]. Co-immunoprecipitation experiments showed that JP-45 is not part of 
the RyR1 macromolecular complex but rather it interacts with calsequestrin via its 
luminal carboxy-terminal domain and with Cav1.1, through its cytoplasmic amino 
terminus. Skeletal muscles of young JP-45 KO mice exhibit characteristics of muscles 
from aged mice such as decreased levels of Cav1.1 content/density in the SR 
membrane [138].  
Parvalbumin  	
Parvalbumin is a high-affinity calcium-binding protein found in a limited number of 
vertebrate tissues, including skeletal muscle and specific nerve cells. The highest 
levels of parvalbumin are found in the fast-contracting and fast-relaxing skeletal 
muscles, while in slow-twitch skeletal muscles, cardiac and smooth muscles, little or 
no parvalbumin is expressed. Parvalbumin contains two high-affinity Ca2+-binding 
sites that are occupied by Mg2+ under resting conditions. Upon cell activation, [Ca2+]i 
rises to micromolar levels, and Mg2+ ions are replaced by calcium ions. The Ca2+ 
association rate of parvalbumin is slower than the rate of Ca2+binding to troponin C. 
For that reason, Ca2+ binds preferentially to troponin C during muscle activation, and 
the parvalbumin-buffering activity is delayed. On the basis of these observations, 
parvalbumin is expected to promote the relaxation of fast-contracting skeletal muscles 
[139]. 
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1.2.4 Ryanodine receptor related neuromuscular disorders  
 
Mutations in both receptors RYR1 and RYR2 have been linked to a number of genetic 
diseases	 [140, 141]. So far there is no described disease phenotype associated with 
mutations in RYR3.  
 
Most of the mutations in RYR1 and RYR2 are found at domain-domain boundaries, 
either in between the three domains or at interfaces with neighboring RyR domains. 
This indicates that some domain interactions may be disrupted during channel 
opening and that mutations facilitate the opening of the channel by weakening these 
contacts. Most of the mutations are at interfaces with other N-terminal hot spot 
domains, either within or across subunits. The zipper hypothesis, involving 
interactions with the central hot spot region, can apply to only less than one-third of 
the N-terminal mutations [127] 
 
In the section below I will only discuss disorders relating to mutations in RYR1, where 
both dominant and recessive mutations have been identified and are associated with 
several muscle disorders, including Malignant hyperthermia (MH), central core 
disease (CCD), multi-minicore disease (MmD), Centronuclear myopathy (CNM), 
core-rod myopathy and congenital fiber type disproportion (CFTD) [142-144]. 
 
Malignant Hyperthermia 
 
Malignant hyperthermia (MH) is a pharmacogenetic disorder induced by volatile 
anesthetics or depolarizing muscle agents, characterized by muscle rigidity, 
rhabdomylolysis, tachycardia, metabolic acidosis and a fatal rise in body temperature 
[80, 145, 146]. It is typically triggered by the combination of a RYR1 mutation and an 
external compound such as a volatile anesthetic or the muscle relaxant 
succinylcholine. In some cases, stress may serve as an alternative external trigger	
[147] . In general, most MH susceptible individuals have unaffected muscle function 
as long as they are not exposed to triggering agents. Patients with congenital 
myopathies with mutations in RYR1 receptors can be at risk of an MH reaction during 
general anesthesia.  
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During an MH event, an excessive leak of Ca2+ from the SR results in a 
hypermetabolic state, depleting the ATP pool and leading to acidosis. Dantrolene is a 
clinically approved drug to treat MH and acts by decreasing the SR Ca2+ release 
[148]. According to several studies there is a direct interaction between dantrolene 
and RyR1	 [149]. Dantrolene inhibits RyR1 Ca2+ release from HEK 293 cells 
transfected with RYR1 cDNA and appears to inhibit store overload-induced calcium 
release (SOICR)	 [150]. On the other hand, the single-channel behavior of RyR1 
incorporated in planar lipid bilayers appears to be unaffected by dantrolene.  
 
 
Central core disease (CCD) 
 
 
Central core disease is a dominantly inherited neuromuscular disorder characterized  
histologically by centrally located areas of reduced oxidative activity and spanning 
the entire longitudinal axis of the muscle fiber and with clinical features of congenital 
myopathy (Fig. 14) [151].  
 
 
 
 
Figure 14: Histopathologic appearance of typical central core disease. NADH-TR, 
transverse section from the rectus femoris. Marked predominance of dark staining, high 
oxidative type 1 fibres with cores affecting the majority of fibres. Cores are typically well 
demarcated and centrally located (→), but may occasionally be multiple and of eccentric 
location	[151]. 
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The symptoms include hypotonia appearing in infancy or in early childhood with a delay in 
motor development.  Stiffness and weakness of the muscles are a feature of CCD and 
distribution of the weakness is usually proximal with the involvement of the hip girdle and 
axial muscles; in rare cases facial wasting is present as well. As part of the weak facial 
involvement, inability to bury eyelashes fully appears, while the extraocular muscle 
involvement was proposed to be an exclusive indicator for the presence of the recessive 
RYR1 mutations [151]. Cardiomyopathies in general are not associated with CCD. Scoliosis, 
congenital dislocation of the hips, foot deformities are also part of the phenotype of this 
disorder. So far, there has been no association between the number of cores in muscle biopsy 
and the severity of the muscle weakness.  Many patients with CCD are positive for the 
malignant hyperthermia susceptibility (MHS) in vitro contracture test (IVCT) and should be 
considered at risk for malignant hyperthermia during general anesthesia [151].  
Around 40 different missense mutations and small deletions in the human RYR1 gene have 
been associated with CCD [152]. There are three regions of the RyR1 protein where MH and 
CCD causing mutations were identified. The first domain is from residue 1-614, the second 
from 2101-2458 and the third from 3916-4973 [153]. According to recent studies patients 
with CCD predominantly have point mutations and in-frame deletions in the C-terminal 
region of the RYR1 [154]	[155]. 
 
The functional effects of RYR1 mutations associated with CCD have been primarily 
investigated by expressing the mutated RYR1 channel in myotubes derived from RYR1-KO 
mice, in primary myotube cultures and lymphoblastoid cell lines derived from patients. 
According to these studies, there are two mechanisms by which missense mutations affect 
Ca2+ release during ECC.  The first mechanism is by enhancing Ca2+ leak from the SR into 
the cytosol leading to depleted SR stores [156]	 [157]. The second mechanism is the 
“uncoupling model” where the mutations affect the capacity of channels to transport Ca2+ 
from the SR following depolarization or direct ligand activation [156]. It seems that RYR1 
mutations linked to CCD located in the first and second domain are associated with Ca2+ 
leak from the SR, while mutations in the third domain are responsible for EC uncoupling,  
though this might not be exclusive, as some leak-inducing mutations have been identified in 
the third domain as well [152]. 
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Multi-minicore disease (MmD)  
Multi-minicore Disease (MmD) is an inherited neuromuscular disorder which is 
characterized by the presence of multiple areas with reduced oxidative activity (called 
minicores) running along a limited area of the longitudinal axis of the muscle 
fiber.Symptoms of MmD appear in infancy or in early childhood and the most prominent 
ones are hypotonia with delayed motor development. Other symptoms associated with the 
presence of minicores include spinal rigidity, scoliosis and respiratory impairment. These 
are usually indicators of a classical MmD phenotype. Since it appears  in life, feeding 
problems can be present and slow the rate of growth and weight gain. Axial muscle 
weakness in the neck and trunk area are common and indicative  of MmD.  
Clinical characteristics: 
Multiminicore disease (MmD) is broadly classified into four groups:  
• Classic form (75% of individuals) 
• Moderate form, with hand involvement (<10%) 
• Antenatal form, with arthrogryposis multiplex congenita (<10%) 
• Ophthalmoplegic form (<10%) 
In general, the diagnosis of MmD is based on the presence of multiple "minicores" visible 
on muscle biopsy using oxidative stains, identification of static or slowly progressive 
weakness, and absence of findings diagnostic of other neuromuscular disorders. 50% of 
MmD patients have causative mutations in SEPN1 and RYR1 (Fig. 15). 
The severe, classic form of multiminicore disease is usually caused by mutations in the 
SEPN1 gene. This gene encodes a protein called selenoprotein N. Although its function is 
unknown, researchers suspect that it may play a role in the formation of muscle tissue before 
birth but it must also be important for normal muscle function. It is unclear, however, how 
mutations in the SEPN1 gene lead to muscle weakness and other features of multiminicore 
disease [158]. The so called ophthalmoplegic form encompasses patients with weakness and 
wasting of muscles similar to the classic phenotype, however such patients also exhibit 
specific weakness of the extraocular muscles or external ophthalmoplegia that is pronounced 
on abduction and upward gaze. In this group respiratory impairment is not so pronounced as 
in the classic form [159].  
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Predominant hip girdle weakness with relative sparing of respiratory and bulbar muscles 
similar to the pattern in patients with CCD is observed in another subgroup of MmD; some 
patients may show additional marked distal weakness and wasting, predominantly affecting 
the hands in the so called moderate form of MmD with hand involvement. [160]. The pattern 
of selective involvement on muscle imaging is similar to that observed in classic CCD 
caused by dominant RYR1 mutations and distinct from the selective muscle involvement 
described in myopathies due to recessive mutations in the SEPN1 gene. The latter two 
groups may form part of a clinical spectrum rather than distinct entities, as suggested by the 
observation of extra-ocular muscle involvement evolving over time in patients with the 
moderate form of MmD. Few severely affected cases have been reported with antenatal 
onset, generalized arthrogryposis, dysmorphic features and mild to moderate reduction of 
respiratory function.  
 
Figure 15: Schematic representation of the skeletal muscle ryanodine receptor (RYR1) 
gene and distribution of dominant and recessive (*) mutations associated with central 
core disease (CCD, in black) and Multi-minicore Disease (MmD, in red). Dominant 
mutations associated with a CCD phenotype predominantly affect the RYR1 C-terminal domain 
encoding the calcium release channel pore of the ryanodine receptor protein, whereas recessive 
mutations predominantly associated with a MmD phenotype are distributed evenly throughout the 
gene. N-terminal, central and C-terminal mutational hotspots within the RYR1 gene are highlighted 
in grey. (Figure courtesy of Dr Haiyan Zhou) [158].  
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Centronuclear myopathy (CNM) 
 
Centronuclear myopathy (CNM) is a genetically heterogeneous condition characterized by 
the prominence of centrally located nuclei on muscle biopsy and clinical features of a 
congenital myopathy (Fig. 16). The severe X-linked recessive form is associated with 
mutations in the myotubularin1 (MTM1) gene. Dominant mutations in dynamin 2 gene 
(DNM2) and RYR1 and recessive in amphiphysin 2 (BIN1) mutations have been associated 
with a milder  phenotype. Extraocular muscle involvement is common in all forms of CNM. 
The MTM1, DNM2, and BIN1 genes all encode proteins with a role in different aspects of 
membrane trafficking and remodeling [144].  
The most severe X-linked form of the disease is caused by mutation in the Xq28 region 
which encodes MTM1  or the protein called myotubularin.1. Most mutations cause very low 
levels of expression if any of myotubularin in the muscle fibres. This protein plays a role in 
phospholipid signaling as it regulates the levels of PI3phosphate and PI3,5P by 
dephosphorylating these phospholipids. Affected muscle fibers have a phenotype of a 
fetal/immature muscle. Boys with the X-linked recessive form, show very early symptoms, 
with poor muscle tone and severe weakness, including breathing difficulties. Other 
symptoms include undescended testicles (testes retention), weak eye musculature and a 
larger head than normal, with or without hydrocephalus. In the most severe form, 
myotubular myopathy, muscle weakness and respiratory problems are often so severe that 
the child dies during the first year of life. 
The DNM2 mutation on chromosome 19p13.2 is the cause of the autosomal dominant form 
of the disease. The dynamin 2 protein is involved in the formation of muscles cell 
membranes and formation of T tubules. The symptoms of the disease are mild and they 
appear in late childhood or in adult age. Mutations in RYR1 cause the dominant form of the 
disease and symptoms appear in the neonatal period or later. Mutations in MTMR14 and 
MYF6 have been discovered in rare cases causing the dominant form of CNM. The 
phenotypes of the patients are very similar and slightly milder than those caused by DNM2 
or RYR1 mutations and can include respiratory difficulties to stiff joints and scoliosis 
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The recessive form of the disease is caused by mutations in BIN1 which is responsible for 
the expression of the amphiphysin 2, a protein enabling dynamin 2 regulation of T tubule 
formation and transport of membrane proteins within muscle cells. In this form of the 
disease, muscle weakness appears in childhood and initially is most apparent in the upper 
arms, thighs, face and eye muscles. The latter causes squinting and drooping of the upper 
eyelids known as ptosis [151]. All three major forms of centronuclear myopathy are rare 
occurring in less than 10 individuals per 100 000. 
 
 
 
Figure 16: Histopathological features of RYR1-related centronuclear myopathy. 
Haematoxylin and eosin (H&E) (a and c), NADH-tetrazolium reductase (NADH-TR) (b) and 
cytochrome oxidase (COX) (d), stains from muscle biopsies taken from the left quadriceps at 1 year 
(a and b) and the right tibialis anterior at 9 years of age (c and d). With H&E stain at 1 year of age 
(a), there is hypotrophy and hypertrophy of two populations of fibres with numerous central nuclei 
mainly in smaller fibres. The smaller fibres are darker with NADH-TR and show central 
accumulation of stain (b). With H&E stain at 9 years of age (c), in addition to central nuclei there is a 
mild increase in connective tissue and staining for COX shows core-like areas devoid of activity that 
are often central (d, arrows) . Bars = 50 nm. [161]. 
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Congenital fiber type disproportion (CFTD) 	
Congenital fiber type disproportion is a rare muscle disease with first symptoms appearing at 
birth or within the first five years of life.  Most apparent symptoms include loss of muscle 
tone (hypotonia) and generalized muscle weakness (myopathy) particularly in the muscles of 
the shoulders, upper arms, hips and thighs. Weakness can also affect muscles of the face and 
muscles controlling eye movement (EOM) and in some cases causing droopy eyelid (ptosis). 
If the muscle weakness is pronounced scoliosis appears, in addition to dislocated hips and 
the permanent fixation of joints in a flexed position (contracture). Delays in motor 
development are present in the majority of cases.  
Establishing the correct diagnosis for this disease can be quite demanding, as the changes 
occurring in the muscle tissue can appear in association with other disorders such as 
congenital muscle disorders, spinal muscular dystrophy, metabolic conditions, etc. In some 
cases CFTD is inherited as autosomal recessive or dominant trait [162]. Approximately 30% 
of patients have mild to severe respiratory involvement and feeding difficulties. It is 
estimated that up to 25 percent of affected individuals experience severe muscle weakness at 
birth and die in infancy or childhood. Muscle weakness generally does not worsen over 
time, and in some cases may improve. The histochemical pattern of muscle biopsies includes 
predominance of the type 1 fibers, which are around 12% or more smaller than type 2 fibers. 
Type 2 fibers remain normal or hypertrophic [162].  
Mutations in the TPM3 have been identified as common cause of CFTD. Mutations in the α-
skeletal actin (ACTA1) gene have been identified in severe cases of CFTD, but the molecular 
mechanisms leading to disproportion in fiber size are unknown [163], it is still unknown if 
the ACTA1 mutations are  involved in the milder cases of CFTD. Causative mutations have 
been identified in TPM2 and SEPN1 as well. The genetic cause is still not known for 
approximately 50% of the cases.  
 
Recently in a study of Clarke at al. mutations in RYR1 were identified in 4 families with 
typical CFTD in whom no other genetic cause was found. From the cohort of patients used 
in this study it was estimated that 10-20% of CFTD cases are due to mutations in RYR1 
[143]. The pathophysiological effect of the RYR1 mutations is not known, though reduced 
channel activity as a consequence of the low expression of RyR1 in the muscle of  some 
patients with recessive form of the disease has been postulated [164].The presence of 
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ophtalmoplegia could be a specific clinical indicator for the presence of mutations in RYR1 
in the CFTD patients, since this symptom is not present in patients with other genetic causes. 
The difficulty however is that in milder cases, ophthalmoplegia might not be apparent and 
therefore hard to detect [165]. 
 
Although there was no family history of MH in any of the reported families with RYR1 
mutations the novel missense mutations may translate into susceptibility to MH in 
heterozygous mutation carriers. Since mutation of RYR1 appears to be a common cause of 
CFTD, it should be recommended that MH precautions are taken for anesthetics in CFTD 
patients who do not have a genetic diagnosis [143]. To date molecular testing is clinically 
available for all genes and completes the diagnosis. 	
 
1.3 Calcium influx and spontaneous calcium events in 
muscle cells 
 
1.3.1 Excitation-coupled calcium entry (ECCE) 
 
Calcium influx in muscle cells is operated by two main mechanisms: excitation-coupled 
Ca2+ entry (ECCE) and store-operated Ca2+ entry (SOCE). ECCE is a form of Ca2+ entry 
from the extracellular environment into the myoplasm, which requires the interaction 
between DHPR and RyR1 as it was shown that in dyspedic and dysgenic myotubes ECCE 
does not occur. ECCE is activated in muscle cells following prolonged membrane 
depolarization. 	
ECCE is enhanced in myotubes expressing RYR1 constructs that carry mutations causing 
malignant hyperthermia in humans. This increase in ECCE may contribute to the 
pathophysiological increase in intracellular Ca2+ that occurs during episodes of malignant 
hyperthermia. It appears that ECCE may be important in normal skeletal muscle as well, to 
help maintain force generation during tetanic stimulation. ECCE is blocked by 2-aminoethyl 
diphenylborate (2-APB), SKF 96356, La3+, Gd3+ and 50µM nifedipine. ECCE can occur 
without any store depletion or in cells in which stores are fully depleted [40]. 
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1.3.2 Store-operated calcium entry (SOCE) 		
SOCE was originally characterized in non-excitable cells but was studied in skeletal muscles 
following the discovery of stromal interaction molecule 1 (STIM1) and Orai1. SOCE is a 
process whereby Ca2+ influx across the plasma membrane is activated in response to 
depletion of intracellular Ca2+ stores in the ER/SR, thus it is an important process involved 
in maintaining intracellular calcium stores.  
STIM1 is a transmembrane phosphoprotein containing several domains which include an 
EF-hand domain, a sterile-α-motif (SAM) domain at the N-terminus, and two coiled-coil 
regions and a proline-rich region at the C-terminus. The EF-hand domain of STIM1 has a 
high affinity for calcium and is located in the lumen of the endoplasmic reticulum (ER), 
where it is thought to sense changes in calcium store content. The coiled-coil domains are 
located in the cytosolic C-terminus and are important for oligomerization and punctae 
formation which occur during the activation of store-operated calcium (SOC) channels. The 
Orai channel family consists of three family members that form a highly selective calcium 
channel by tetramerization. STIM1 and Orai1 are both expressed in skeletal muscle, and 
mice lacking STIM1 and Orai1 display reduced muscle mass.  
 
Three basic models for SOCE have been proposed in recent years: two of these involve 
conformational coupling between the Transient Receptor Potential channels (TRPC) and 
either the inositol trisphosphate receptor (IP3R) and/or RYR1 and a third that involves the 
physical interaction of STIM1 and Orai1 [166]. 
 
1.3.3 Sparks 	
The term Ca2+ spark was used for the first time by Chen and Lederer to describe 
spontaneous  subcellular Ca2+ release events [167]. Ca2+ sparks are small, brief and very 
localized releases of Ca2+ and were originally described in cardiac myocytes and later in 
amphibian skeletal muscles. They appear spontaneously in frog skeletal muscle fibers at rest 
and at higher frequency during depolarization [168]. In general, sparks and other local Ca2+ 
events are described and quantified by their amplitude expressed in [Ca2+] or as normalized 
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increase of fluorescence, ∆F/F0, by the duration measured as full duration at half maximal 
amplitude (FDHM) and  by their width measured as full width at half maximal amplitude 
(FWHM). The decay of the sparks occurs through diffusional dissipation of the Ca2+ signal 
away from its source [169]. 	
Ca2+ sparks were also discovered in smooth muscle cells two years after their initial report in 
cardiomyocytes [170]. In unstimulated single cardiac myocytes, a Ca2+ spark appears 
suddenly, reaches its peak of about a two-fold increase in fluorescence intensity within 10 
ms, and disappears in a matter of 20 ms. It is defined by an area of  ~2.0 µm in diameter. 
Spontaneous Ca2+ sparks do not require Ca2+ entry into the myocyte through DHPR or by 
other channels on the plasma membrane. At a resting membrane potential of -80mV 
spontaneous sparks appear even when extracellular Ca2+ is removed for a short period [53].  
 
Ca2+ sparks also occur even after the L-type calcium channels have been blocked 
pharmacologically. Saponin-permeabilised myocytes also exhibit sparks indicating that the 
membrane integrity is not a prerequisite for these events. It is now accepted  that 
spontaneous Ca2+ sparks are due to the small but limited opening of RyRs that depends on 
many factors including [Ca2+]i and [Ca2+]SR, the free Ca2+ concentration in the cytosol and in 
the SR lumen, respectively. At supramicromolar concentrations, ryanodine abolishes sparks 
altogether.  
 
Ca2+ sparks occur in skeletal and smooth muscles, cardiac myocytes, neuroendocrine cells 
and neurons containing different isoforms of RyRs. Localized Ca2+ release events with 
characteristics similar to sparks have also been observed in some non-excitable cells, 
including endothelial cells [167].	
 
In vertebrate skeletal muscles, type 1 RyRs form a “double checkerboard” arrangement 
where unconnected RyRs are in direct contact with those that are engaged with DHPRs. 
Under normal conditions in mammalian skeletal muscles sparks do not occur as the highly 
ordered checkerboard conformation is thought to inhibit sparks as the DHPR blocks RyR1 
Ca2+ release. Experimentally under non-physiological conditions and under hypo-osmotic 
stress, Ca2+ sparks were induced in isolated mouse skeletal muscle fibers [167]. 
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CHAPTER 2: RESULTS 
 
2.1  Excitation-contraction coupling and Ca2+ homeostasis in 
human craniofacial muscles 
 
2.1.1 Introduction  
 
There are approximately 60 distinct skeletal muscles in the vertebrate head that control food 
intake, facial expression and eye movement. These muscles develop in a manner that is 
tightly coordinated with other craniofacial tissues. In recent years, interest in this unique 
group of skeletal muscles has significantly increased, with the accumulation of new 
information in terms of molecular profiling and gene targeting studies. From a clinical point 
of view they are coming into the spotlight, especially when it comes to diseases that affect 
them (strabismus, laryngeal dystonias, facial paralysis and others), but more intriguing is 
their selective and non-uniform response in different neuromuscular disorders, where some 
of them are spared and others heavily affected [4]. For this reason we were interested to 
resolve some of the questions regarding the similarities and differences between different 
groups of head muscles in the context of neuromuscular disorders. 
 
Keeping this in mind, we investigated human extraocular muscle samples at different points 
of maturity, either in mature muscles isolated during corrective eye surgery or in myotubes 
derived in culture from the muscle biopsies. Our aim was to define the Ca2+ handling 
properties of these muscles. Defining the characteristics of EOM as well as those of the 
distinct but spatially close muscles known as orbicularis oculi was also one of the our aims, 
Indeed, we found significant differences between human EOM, OO and LM in terms of 
protein levels of different ECC components as well as in the regulation of  Ca2+ homeostasis.  
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2.1.2 Publication – Characterization of the excitation contraction 
coupling in human extraocular muscles 
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Excitation–contraction coupling (ECC) is the physiological
mechanism whereby an electrical signal detected by the
dihydropyridine receptor, is converted into an increase in [Ca2+ ],
via activation of ryanodine receptors (RyRs). Mutations in
RYR1, the gene encoding RyR1, are the underlying cause of
various congenital myopathies including central core disease,
multiminicore disease (MmD), some forms of centronuclear
myopathy (CNM) and congenital fibre-type disproportion.
Interestingly, patients with recessive, but not dominant, RYR1
mutations show a significant reduction in RyR protein in muscle
biopsies as well as ophthalmoplegia. This specific involvement
of the extraocular muscles (EOMs) indicates that this group of
muscles may express different amounts of proteins involved in
ECC compared with limb muscles. In the present paper, we
report that this is indeed the case; in particular the transcripts
encoding RyR3, cardiac calsequestrin (CSQ2) and the α1 subunit
of the cardiac dihydropyridine receptor are up-regulated by at
least 100-fold, whereas excitation-coupled Ca2+ entry is 3-fold
higher. These findings support the hypothesis that EOMs have a
unique mode of calcium handling.
Key words: calcium homoeostasis, excitation–contraction
coupling, gene expression.
INTRODUCTION
Extraocular muscles (EOMs) are among the fastest and most
fatigue-resistant skeletal muscles [1]. More than 20 years ago,
they were categorized as a separate group of muscles or ‘allotype’
since they represent a unique group of highly specialized muscles,
anatomically and physiologically different from other skeletal
muscles [2]. Indeed, their embryonic origin is distinct from that
of limb muscles: the former, together with the striated muscles of
the face, jaw and throat, develop from the first seven somitomeres
whereas the latter derive from somites [3]. In humans, there are
six types of EOMs and they are characterized by the presence of
two layers: the inner global layer and the outer orbital layer [4].
The fibre type classification of limb muscles does not fit the six
fibre types described in EOMs [1] and the innervation of EOMs
is also different, as they are innervated by cranial nerves and
contain both singly innervated muscle fibres (SIFs) and multiply
innervated fibres (MIFs), whereas mammalian limb muscle fibres
are singly innervated by motoneurons originating from the spinal
cord [5]. The distinct origin and innervation of EOMs are probably
responsible for the differences in gene and protein expression that
have been described in mammalian EOMs [6].
The ryanodine receptor 1 (RyR1) is the calcium channel of
striated skeletal muscle responsible for releasing Ca2+ from the
sarcoplasmic reticulum leading to muscle contraction [7,8]. Over
the last two decades, more than 200 mutations in RYR1 (the gene
encoding RyR1) have been identified in the human population and
linked to neuromuscular disorders and/or the pharmacogenetic
disorder malignant hyperthermia [9,10]. Whereas the dominant
RYR1 mutations are predominantly associated with central
core disease and/or a susceptibility to malignant hyperthermia,
recessive mutations are found in patients with multiminicore
disease (MmD), centronuclear myopathy (CNM) and congenital
fibre-type disproportion [10–15]. Interestingly, patients with
recessive, but not dominant, RYR1 mutations show a decreased
amount of RyR1 protein in biopsied muscles, as well as specific
involvement of EOM (ophthalmoplegia) [11–14,16]. Selective
involvement of EOM or lack thereof, also characterizes particular
neuromuscular diseases: in myasthenia gravis and mitochondrial
myopathies they are the first and most affected muscle group
[17] whereas they are characteristically spared from pathology
in aging, Duchenne muscular dystrophy and congenital muscular
dystrophy [18–20]. Such sparing of EOM in muscular dystrophies
has been attributed to constitutive differences between EOM
and other skeletal muscles [20] but the factors controlling these
differences remain largely unknown.
In order to help clarify the cause(s) for the specific
involvement of EOM in patients with recessive RYR1 mutations,
we investigated their excitation–contraction coupling (ECC)
machinery and calcium homoeostasis. Our results show that there
are significant differences between leg muscles (LMs) and EOM;
in particular the latter have developed a chimaeric configuration in
that they express significantly lower levels of RyR1, theα1 subunit
of the dihydropyridine receptor (Cav1.1) and calsequestrin-1
(CSQ1), whereas the cardiac isoforms of the Cav1.2 and CSQ2
are highly expressed as is RyR3. Such changes result in different
characteristics of calcium homoeostasis, as myotubes explanted
from EOM exhibit a large component of excitation coupled Ca2+
entry (ECCE). The results of the present study shed light on
the underlying causes leading to EOM involvement in congenital
muscle disorders due to RYR1 mutations causing a decrease in
RyR1 protein.
Abbreviations: Cav, α1 subunit of the dihydropyridine receptor; CCD, charge-coupled device; CSQ, calsequestrin; ECC, excitation–contraction coupling;
ECCE, excitation-coupledCa2+ entry; EOM, extraocularmuscle; LM, legmuscle; NA, numerical aperture; qPCR, quantitative real-time PCR; RyR, ryanodine
receptor; SERCA, sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase; TIRF, total internal reflection fluorescence.
1 To whom correspondence should be addressed (email susan.treves@unibas.ch).
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EXPERIMENTAL PROCEDURES
Human muscle cell cultures
Primary muscle cell cultures were established from fragments of
quadriceps muscles obtained from biopsies of healthy donors (five
donors) and EOM samples obtained from patients undergoing
squint corrective surgery (four donors), as described previously
[21,22]. Cells were cultured on laminin-coated 0.17-mm-thick
glass coverslips in growth medium (Skeletal Muscle Cell Growth
medium; Promo Cell) and induced to differentiate into myotubes
by culturing them in differentiation medium (Skeletal Muscle Cell
Differentiation medium; Promo Cell) for 7–14 days. This research
was carried out in accordance with the Declaration of Helsinki
(2013) of the World Medical Association and was approved by
the Ethikkommission beider Basel (permit number EK64/12); all
subjects gave written informed consent to carry out this work.
Calcium measurements
Myotubes were loaded with fura-2 (Calbiochem) or fluo-4
(Life Technologies) (final concentration 5 µM) in differentiation
medium for 30 min at 37 ◦C, after which the coverslips were
mounted on to a 37 ◦C thermostatically-controlled chamber
which was continuously perfused with Krebs–Ringer medium;
individual cells were stimulated by means of a 12- or 8-way
100 mm diameter quartz micro-manifold computer-controlled
microperfuser (ALA Scientific Instruments), as described
previously [22]. For global changes in the intracellular Ca2+
concentration, the fluorescent ratiometric Ca2+ indicator fura-2
was used. Online measurements were recorded using a fluorescent
Axiovert S100 TV inverted microscope (Carl Zeiss) equipped
with a 20× water-immersion FLUAR objective [0.17 numerical
aperture (NA)] and filters (BP 340/380, FT 425, BP 500/530)
and attached to a Cascade 128+ CCD (charge-coupled device)
camera. Changes in fluorescence were analysed using Metamorph
imaging software (Molecular Devices) and the average pixel
value for each cell was measured at excitation wavelengths
of 340 nm and 380 nm as described previously [21,22]. Fura-
2 fluorescent ratio signals were converted into [Ca2+ ] using
the fura-2 Ca2+ imaging calibration kit from Molecular
Probes/Invitrogen following the manufacturer’s instructions, as
previously described [23]. The dynamics of [Ca2+ ] influx were
investigated by TIRF (total internal reflection fluorescence)
microscopy using the fast Ca2+ indicator fluo-4, as described
previously [24]. Briefly, differentiated human myotubes were
mounted on a thermostatically controlled perfusion chamber,
bathed continuously in Krebs–Ringer containing 2 mM Ca2+ .
ECCE was measured after the application of 60 mM KCl
to myotubes pre-treated with 50 µM ryanodine (Calbiochem) to
block RyR1-mediated Ca2+ release. Nifedipine (50 µM)
(Calbiochem) was used to block the dihydropyridine receptor
or 0.5 mM EGTA to chelate Ca2+ . Online fluorescence images
were acquired using an inverted Nikon TE2000 TIRF microscope
equipped with an oil immersion CFI Plan Apochromat 60× TIRF
objective (1.49 NA) and an electron multiplier Hamamatsu CCD
camera C9100–13. Data were analysed using Metamorph imaging
software (Molecular Devices).
Quantitative real-time PCR
Total RNA was extracted from muscle biopsies using TRIzol®
(Invitrogen) and following the manufacturer’s protocol. The RNA
was first treated with DNase I (Invitrogen) and then 1000 ng
were reverse-transcribed using the high-capacity cDNA reverse
transcription kit (Applied Biosystems); cDNA was amplified
by quantitative real-time PCR (qPCR) using SYBR Green
technology (Fast SYBR Green Master Mix, Applied Biosystems)
as described previously [25]. The sequence of the primers used to
amplify and quantify the different genes is given in Supplementary
Table S1. qPCR was performed on a 7500 Fast Real-Time PCR
machine from Applied Biosystems using the 7500 software v2.3.
The standard protocol was selected and the running method
consisted of a holding stage at 50 ◦C for 20 s and a denaturing
step at 95 ◦C for 10 min, followed by 40 cycles of denaturing
at 95 ◦C for 15 s and an extension step at 60 ◦C for 1 min. Gene
expression was normalized to expression ACTN2, which is present
in all muscle fibre types. Results are expressed as fold change
compared with expression of the gene in LMs.
Immunofluorescence
Glass coverslip grown and differentiated myotubes were fixed
with 4% paraformaldehyde (made in Phosphate buffered saline
(PBS)), permeabilized with 1% Triton in PBS for 20 min and
processed as previously described [24]. The following antibodies
were used: mouse anti-RyR1 (Thermo Scientific; MA3–925),
goat anti-Cav1.1 (Santa Cruz Biotechnology, sc-8160), rabbit anti-
Cav1.2 (Santa Cruz Biotechnology, sc-25686), Alexa Fluor® 488-
conjugated chicken anti-rabbit, Alexa Fluor®-conjugated donkey
anti-goat IgG (Life Technologies) and Alexa Fluor®-conjugated
goat anti-mouse IgG (Life Technologies). Cells were stained with
DAPI (Life Technologies) to visualize nuclei and observed using
a Nikon A1R confocal microscope with a CFI Apo TIRF 100×
(1.49 NA) objective.
Electrophoresis and immunoblotting
The total sarcoplasmic reticulum fraction was isolated from
flash-frozen muscle samples (human EOM, quadriceps muscles
and mouse heart) stored in liquid nitrogen as previously
described [26]. Protein concentration was determined using
Protein Assay Kit II (Bio-Rad Laboratories) using BSA as
a standard. SDS/PAGE, protein transfer on to nitrocellulose
membranes and immunostaining were performed as described
previously [26]. The following primary antibodies were used:
mouse anti-RyR1 (Thermo Scientific, MA3–925), goat anti-
Cav1.1 (Santa Cruz Biotechnology, sc-8160), rabbit anti-Cav1.2
(Santa Cruz Biotechnology, sc-25686), rabbit anti-CSQ-1 (Sigma,
C-0743) and CSQ2 (Abcam, ab-3516), goat anti-SERCA1
(sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase 1) (Santa
Cruz Biotechnology, sc-8093), goat anti-SERCA2 (Santa Cruz
Biotechnology, sc-8095), mouse anti-sarcalumenin (Thermo
Scientific, MA3-932), goat anti-junctophilin1 (Santa Cruz
Biotechnology, sc-51308). Secondary horseradish peroxidase
conjugates were Protein G–horseradish peroxidase (Sigma,
P8170) and horseradish peroxidase-conjugated goat anti-mouse
IgG (Sigma, A2304). The immunopositive bands were visualized
by chemiluminescence using the Super Signal West Dura kit
(Thermo Scientific) or the chemiluminescence kit from Roche.
Statistical analysis
Statistical analysis was performed using Student’s t test for two
populations. Values were considered significant when P< 0.05.
When more than two groups were compared, analysis was
performed by the ANOVA test followed by the Bonferroni post-
hoc test, using the GraphPad Prism 4.0 software. The Origin Pro
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Figure 1 Expression of ECC transcripts and proteins in human EOM biopsies
(A) Gene expression was carried out by qPCR as described in the ‘Experimental Procedures’ section. Each reaction was carried out in triplicate, in pooled muscle samples from 4–5 biopsies from
different individuals. Expression levels were normalized to ACTN2 expression. Results are expressed as mean fold change (AU, arbitrary units) of transcripts in EOM compared with LMs, the latter
were set as 1. Results were analysed using Student’s t test (***P < 0.0001). (B) Western blot analysis of total sarcoplasmic reticulum proteins in human EOM and LMs. Twenty micrograms of protein
were loaded per lane and separated on SDS/6% PAGE or SDS/10% PAGE. Blots were probed with the indicated antibodies. Histograms represent the mean+− S.E.M. band intensity normalized to
SERCA2 content (*P < 0.05; **P < 0.005; ***P < 0.0001).
8.6 software was used for generating dose–response curves and
calculating EC50 values.
RESULTS
Excitation–contraction coupling gene and protein expression levels
in human EOM
Figure 1(A) shows the expression level as assessed by qPCR,
of the main genes involved in skeletal muscle ECC in EOM
biopsies, compared with quadriceps biopsies from healthy donors;
the latter were taken as the reference tissue and the expression of
the different set of muscle-specific genes in human quadriceps
was set as 1. The results represent the mean expression levels
of samples pooled from four to five biopsies and are expressed
on a logarithmic scale. The most interesting finding is that the
expression levels of major genes involved in skeletal muscle
ECC, namely RYR1, CACNA1S, SERCA1 and CASQ1 were
∼10-fold lower (P< 0.0001) than in LM biopsies. Intriguingly,
the transcript level of RYR3 was ∼800-fold higher in EOM
(P< 0.0001). A second interesting result was that the expression
level of CASQ2 was found to be ∼100-fold higher in EOM
(P< 0.0001) as was that of the structural proteins TRDN and
ASPH1 (∼10-fold and∼1000-fold respectively; P< 0.0001) and
of the calcium buffering and binding proteins SRL and PVALB
(10-fold; P< 0.0001) As expected, the MYH1 transcript level
was significantly lower in EOM (100-fold; P< 0.0001) than
in LMs, since this isoform is mainly expressed in slow-twitch
muscles. In contrast, the transcript of MYH13, which is the
isoform characteristically expressed in eye muscles, was ∼5000-
fold higher in EOM (P< 0.0001), corroborating the validity of
our assay. Taken together, these results indicate that the gene
expression pattern of the main components involved in ECC of
human EOM is specific and distinct from that of other striated
skeletal muscles.
In order to confirm the changes in gene expression on the protein
level, we prepared the total sarcoplasmic reticulum fractions and
probed them with a panel of antibodies against skeletal and
cardiac ECC protein components. The protein expression levels
were then normalized for SERCA2 whose content was similar
in LM and EOM as assessed by real time PCR (Figure 1A) and
immunoblotting. Figure 1(B) shows the representative Western
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Figure 2 Cellular localization of RyR1, Cav1.1 and Cav1.2 in differentiated EOM-derived myotubes
Human myotubes were stained as described in the ‘Experimental Procedures’ section and visualized with a Nikon A1R confocal microscope equipped with a CFI Apo TIRF 100× objective (1.49 NA).
(A) anti-RyR1 (red), (B) anti-Cav1.1 (green), (C) merged image of anti-RyR1, anti-Cav1.1 and DAPI (blue); orange pixels show co-localization between RyR1 and Cav1.1. (D) anti-RyR1 (red), (E)
anti-Cav1.2 (green), (F) merged image of anti-RyR1, anti-Cav1.2 and DAPI (blue). Scale bar, 20µm.
blots and quantitative histograms, as can be seen, for RyR1,
Cav1.1, SERCA1 and CSQ1 the protein levels are decreased by
more than 50% in EOM compared with LM samples. The cardiac
isoform of the RyR2 was not detectable in EOM (Supplementary
Figure S1) whereas Cav1.2, the cardiac isoform of the Cav CSQ2,
as well as sarcalumenin, were significantly up-regulated in EOM
(2-fold for Cav1.2 and by 50% for CSQ2 and sarcalumenin);
qPCR could not be used reliably to compare the expression levels
of the Cav1.2 transcript because of its extremely low level of
expression in leg skeletal muscles (the reference tissue in the
qPCR); its level of expression is comparable with that found in
mouse heart microsomes (Supplementary Figure S1).
Ca2+ homoeostasis in EOM cultured myotubes
Muscle biopsies have been used as a starting material to
obtain primary muscle cultures from patients with different
neuromuscular disorders and the myotubes that have been
obtained have been a useful model to study ECC under normal
and pathological conditions [21,22,24,25]. In the present study, we
successfully used a protocol similar to that used for LM biopsies,
in order to obtain EOM-derived myotubes (Figure 3A). Once a
sufficient number of myoblasts grew out of the biopsy, they were
further expanded and then induced to differentiate into myotubes.
Figure 2 shows photomicrographs of myotubes stained with anti-
RyR1 (red, Figure 2A), anti-Cav1.1 (green, Figure 2B) merged
plus DAPI (Figure 2C) and anti-RyR1 (red, Figure 2D), anti-
Cav1.2 (green, Figure 2E) and merged plus DAPI (Figure 2F) and
observed by confocal microscopy. As can be seen, the myotubes
are positive for RyR1 and Cav1.1 and the two proteins co-
localize within an intracellular membrane compartment, but as
previously established [25] their distribution is punctuated, not
highly regular and lacks the distinct structure observed in mature
fibres. The localization of Cav1.2, however, is clearly different
from that of Cav1.1 (compare Figures 2B and 2E); indeed the
Cav1.2 appears to be almost exclusively localized on the plasma
membrane. These results point to a potential alternative form of
ECC in EOM-derived myotubes and we next studied calcium
homoeostasis in these cells. Results from LM-derived myotubes
from five donors and EOM-derived myotubes from four donors
were pooled and averaged. Figure 3(B) shows that the KCl-
induced Ca2+ release from intracellular stores (in the presence of
100 µM La3+ and therefore reflecting skeletal ECC) was similar
in LM and EOM-derived myotubes. However, in EOM-derived
myotubes the EC50 for 4-chloro-m-cresol-induced Ca2+ release
was increased (332+− 26 and 234+− 58 µM for EOM and LM
respectively). Additionally, Figure 3(C) shows that the resting
[Ca2+ ] in EOM-derived myotubes is significantly lower than that
of LM-derived myotubes (P< 0.0001; Student’s t test), whereas
the size of the rapidly releasable intracellular Ca2+ stores is more
than 2-fold larger in EOM-derived myotubes compared with LM-
derived myotubes (Figure 3D).
Plasma membrane depolarization of skeletal muscle cells
is accompanied by Ca2+ influx through the dihydropyridine
receptor and this phenomenon is defined as ECCE [24,27,28].
We next studied ECCE in EOM-derived myotubes using a
TIRF microscope [24]. The top panels in Figure 4(A) show a
representative myotube pre-treated with 50 µM ryanodine and
stimulated with 60 mM KCl; Figure 4(B) shows a representative
Ca2+ influx trace initiated by the application of 60 mM KCl
in EOM-derived myotubes (continuous line) and LM-derived
myotubes (dotted line). The change in fluo-4 fluorescence
represents Ca2+ influx via the dihydropyridine receptor and not
release from stores as: (i) myotubes were incubated with 50 µM
ryanodine in order to block Ca2+ release via RyR; (ii) pre-
incubation of myotubes with ryanodine plus 50 µM nifedipine
blocked the Ca2+ increase (Figure 4C); and (iii) Ca2+ influx was
inhibited when the experiment was performed in Krebs–Ringer
solution containing 0.5 mM EGTA (Figure 4C). Thus, compared
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Figure 3 Global calcium homoeostasis of EOM-derived myotubes
Myotubes were loaded with 5µM fura-2 and perfused with Krebs–Ringer medium containing 2 mM CaCl2. For KCl-induced Ca2+ release, individual cells were perfused with Krebs–Ringer plus
100µM La3+ and the indicated concentration of KCl was applied using a microperfusion system. (A) Brightfield photomicrograph of a fully-differentiated myotube 5 days after differentiation. (B)
KCl dose–response curve of EOM-derived myotubes (filled circles, continuous line) and LM-derived myotubes (empty circles, dotted line). Curves show the changes in peak calcium, expressed as
[Ca2+ ] in nM. Each point represents the mean+− S.E.M. of a minimum of four to ten different cells. (C) Mean+− S.E.M. resting [Ca2+ ] in EOM and LM-derived myotubes. (D) Total amount of Ca2+
in the sarcoplasmic reticulum. The total amount of rapidly releasable Ca2+ in the stores was determined by calculating the area under the curve of the transient induced by the application of 1µM
ionomycin plus 500 nM thapsigargin in Krebs–Ringer containing 0.5 mM EGTA. Values represent the mean+− S.E.M. of the indicated number of cells. ***P < 0.0001. Experiments were performed
on LM-derived myotubes from five donors and EOM-derived myotubes from four donors. The values represent mean intracellular calcium measurements from coverslips measured on different days.
with LM-derived myotubes, depolarization-induced Ca2+ influx
in EOM myotubes was 3-fold higher (Figure 4D).
DISCUSSION
In the present study, we characterized the ECC machinery of
human EOM and report that these muscles are particular in as
much as they express important components of the cardiac ECC
machinery; in addition, we report for the first time that primary
muscle cell cultures can be obtained from biopsies of patients
undergoing squint or corrective surgery. Such myotubes maintain
their phenotypic characteristics since they exhibit intracellular
calcium regulation that is enhanced compared with primary
cultures of LM-derived myotubes. The present study is important
as it shows the feasibility of performing such experiments not
only in biopsies obtained from normal individuals, but also can
be extended to patients suffering from neuromuscular disorders
causing ophthalmoplegia.
In a previous study, Porter et al. [29] used a bioinformatic gene
profiling approach to identify key differences between murine
EOM, LMs and jaw muscles. In their study, they scanned the
expression pattern for transcripts encoding proteins involved
in transcriptional regulation, signal transduction, intermediary
metabolism and sarcomeric ECC. As far as the ECC coupling
machinery is concerned, our results do not support their findings
as we found significant changes between leg and EOM expression
of CSQ1 and CSQ2, RyR1, SERCA1 and Cav1.1, triadin,
sarcalumenin and parvalbumin and no change in mitsugumin-
29. Such inconsistencies may be due to the fact that (i) they
used mouse skeletal muscle and we used human biopsies, (ii)
we used qPCR on pooled samples; (iii) the biopsies we analysed
were derived from patients with strabismus and therefore not
‘normal’ muscles. Indeed the pattern of expression of transcripts
in strabismic and normal EOMs has been reported to be different
[30]; and (iv) we normalized all qPCR results for the content of
the muscle-specific gene ACTN2. In support of our findings, it
was shown that there are important differences between human
EOM and those of other species [31].
An interesting observation of the present report is that EOM
express low levels of RyR1 but high levels of RyR3, a finding
that may explain why patients with recessive ryanodinopathies
leading to decreased expression of RyR1 characteristically show
extraocular involvement [11,15] whereas those with dominant
RYR1 mutations do not. It is plausible that since the levels of
expression of RyR1 are low in EOM, mutations leading to a further
decrease in its level of expression will severely affect muscle
function, leading to ophthalmoplegia. In this context, it should be
mentioned that the higher levels of RyR3 expressed in EOM do not
compensate for the decrease in RyR1, indicating that the RyR3
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Figure 4 EOM-derived myotubes exhibit a larger depolarization-induced Ca2+ influx compared with LM-derived myotubes
Ca2+ influx induced by addition of 60 mM KCl was monitored using a TIRF microscope in myotubes pre-incubated with 50µM ryanodine to block RyR1-mediated Ca2+ release and loaded with
5µM fluo-4. (A) Top panels, pseudocoloured ratiometric images (peak fluorescence after addition of KCl/resting fluorescence) of fluo-4 fluorescence changes after application of KCl to EOM-derived
myotubes. (B) Representative ECCE trace showing changes in fluo-4 fluorescence in a EOM-derived myotube (continuous line) and LM-derived myotube (dotted line). (C) Histogram depicting
mean+− S.E.M. peak increase of fluo-4 fluorescence induced in EOM-derived myotubes by 60 mM KCl alone (white bar), in cells pre-incubated with 50µM nifedipine (grey bar) or in cells stimulated
with Krebs–Ringer containing 0.5 mM EGTA (black bar). Statistical analysis performed by the ANOVA test followed by the Bonferroni post-hoc test; *P < 0.02, **P < 0.005. (D) Mean+− S.E.M.
peak increase of fluo-4 fluorescence induced by 60 mM KCl in human EOM-derived myotubes (white bar) compared with LM-derived myotubes (black bar). Experiments were performed on cells
grown from three different biopsies on three different days and results were pooled and averaged. Statistical analysis was performed using Student’s t test; ***P < 0.0001.
isoform must be involved in other aspects of calcium release,
cannot be directly activated by the Cav1.1 voltage sensor and
cannot functionally replace RyR1. On the other hand, EOM also
express high levels of the Cav1.2 and of CSQ [32]; as far as CSQ2
is concerned, it has half the calcium-binding capacity of CSQ1
[33], it is phosphorylated to a higher stoichiometry and at least
50-fold more rapidly [34]. Though the role of phosphorylation
is unclear, it is thought to increase the Ca2+ -binding affinity and
to assure that the levels of Ca2+ near the Ca2+ release sites are
elevated [35]. The observed up-regulation of Cav1.2 is both novel
and intriguing as this isoform is mainly expressed in the heart,
where it functions as a voltage sensor and Ca2+ channel, activating
RyR2 via a Ca2+ -induced Ca2+ release mechanism [36]. In EOM-
derived myotubes, this isoform was clearly distributed on the
plasma membrane and since RyR2 was not detectable in EOM,
either these muscles have evolved a chimaeric cardiac/skeletal
ECC, with Cav1.2 activating RyR1, or Cav1.2 may be coupled
to RyR3 or it may be involved in Ca2+ influx following
plasma membrane depolarization. Such chimaeric expressions
of RyR isoforms are not uncommon in smooth muscle cells
that are reported to express different combinations of calcium
channels and L-type voltage sensors, depending on their tissue of
origin and physiological requirements [37].
Zeiger et al. [38] showed that rat eye muscle-derived
myotubes exhibit superior calcium homoeostasis compared with
leg tibialis anterior-derived myotubes and release double the
amount of calcium after treatment with ionomycin than LM-
derived myotubes. The results of the present study support
and extend these findings; indeed human EOMs not only have
larger intracellular Ca2+ stores and express different calcium-
buffering proteins, but also show lower resting [Ca2+ ] and
enhanced depolarization-induced calcium influx (or ECCE). The
enhanced calcium-handling capacity may be due to the higher
expression levels of CSQ2 and of the calcium-binding proteins
parvalbumin and sarcalumenin. Parvalbumin is a cytosolic high-
affinity Ca2+ -binding protein preferentially expressed in fast
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twitch muscles whose function is to promote muscle relaxation
[39,40], whereas sarcalumenin is localized on the longitudinal
sarcoplasmic reticulum where it is involved in stabilizing the
Ca2+ pump and in maintaining rapid contraction and relaxation
rates [41]. The physiological function of depolarization-induced
calcium influx is far from clear but it is postulated to be important
for refilling of intracellular Ca2+ stores, which is essential
during repetitive stimulation [42,43]. Interestingly EOM-derived
myotubes have significantly larger intracellular calcium stores
and enhanced Ca2+ influx and the latter is probably due to the
high levels of expression of Cav1.2.
A final observation resulting from the present study and from
a previous study [25] concerns the phenotype of satellite cells;
depending on their muscle of origin, be it fast or slow twitch or
EOM, the satellite subpopulations are intrinsically different [44]
and they maintain the specific characteristics particular to the
muscle from which they originated even after explantation and
culture.
In conclusion, the present study provides insights into the
ECC characteristics of human EOM. Reduced expression of
RyR1, CSQ1 and SERCA1 is a feature of great significance
in the context of ophthalmoplegia and neuromuscular disorders.
Taking into account the importance of exquisitely efficient
calcium management in order to achieve the demanding
physiological properties of the EOMs, the increased levels of
CSQ2, parvalbumin and sarcalumenin together with reported
higher depolarization-induced calcium influx and particular high
expression of Cav1.2 indicate that this group of muscles which
is in constant use, relies on a chimaeric skeletal/cardiac ECC
configuration.
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ABSTRACT 
The orbicularis oculi are the sphincter muscles of the eyelids and are involved in 
modulating facial expression.	They differ from both limb and extraocular muscles in their 
histology and biochemistry. Normal orbicularis oculi possess some features which, when 
present in limb or trunk muscles, would be considered consistent with a chronic myopathy 
or dystrophy. Weakness of the orbicularis oculi muscles is present in neuromuscular 
disorders affecting the neuromuscular junction and weakness of facial muscles and ptosis 
have also been described in patients with mutations in RYR1. In the present paper, we 
investigated human orbicularis oculi muscles and found that they are functionally more 
similar to quadriceps than to extraocular muscles in terms of skeletal muscle excitation-
contraction coupling components. In fact, they do not express the cardiac isoform of the 
dihydropyridine receptor, which was found to be highly expressed in extraocular muscles 
and is most likely responsible for the large depolarization induced calcium influx in the 
latter muscles. On the other hand, human orbicularis oculi and extraocular muscles express 
high levels of utrophin and very low levels of dystrophin, while quadriceps express 
dystrophin and low levels of utrophin. The results of the present study highlight the notion 
that myotubes obtained by explanting satellite cells from different muscles are not 
functionally identical and retain the physiological characteristics of their muscle of origin. 
Furthermore our results indicate that sparing of facial and extraocular muscles in patients 
with Duchenne is the result of the higher levels of utrophin expression. 
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INTRODUCTION	
Excitation-contraction coupling (ECC) is the process whereby an electrical signal, 
depolarization of the plasma membrane, is converted into a chemical signal, Ca2+ release 
from the sarcoplasmic reticulum, leading to muscle contraction (Caputo 2010). ECC relies 
on the function of two main Ca2+ channels, the voltage sensing dihydropyridine receptor 
(DHPR) an L-type Ca2+ channel present on the transverse tubules and the ryanodine receptor 
Ca2+ channel (RyR) present on the sarcoplasmic reticulum terminal cisternae. In mammalian 
skeletal muscle ECC is mechanically coupled, that is membrane depolarization causes the 
α1 subunit (Cav1.1) of the DHPR to undergo a conformational change causing it to come in 
direct contact with the RyR1 and leading to release of Ca2+ from the sarcoplasmic reticulum 
(Rios and Pizarro 1991). In mammalian cardiac muscles on the other hand, ECC does not 
rely on mechanical coupling, but rather influx of Ca2+ through the cardiac α1 subunit of the 
DHPR (Cav1.2) activates the cardiac RyR2 leading to release of Ca2+ from the sarcoplasmic 
reticulum (Bers 2002). Thus the functional requirements of heart and skeletal muscle are 
assured by the exquisite specificity of protein isoform expression. This general configuration 
of skeletal and cardiac ECC protein expression was thought to underlie the function of most 
striated muscles; however, in a recent study on the protein composition of human 
extraocular muscles (EOM), we found that hybrid skeletal/cardiac muscle configurations of 
the ECC machinery can exist. Indeed EOM express both the skeletal and cardiac isoforms of 
α1 subunit of the DHPR, rely on influx of Ca2+ from the extracellular environment and 
express not only RyR1 but also RyR3 (Sekulic-Jablanovic, Palmowski-Wolfe et al. 2015).  
Extraocular muscles (EOM), the fastest muscles in the body, derive from 
somitomeres (preotic mesodermal segments) (Wright, Hengst et al. 2007). There are six 
extraocular muscles distributed in three antagonistic pairs of muscles that finely control eye 
movements (Spencer and Porter 1988); they are innervated by three cranial nerves (III, IV 
and VI) (Sadeh and Stern 1984). EOM are highly specialized and can be either singly 
innervated or multiply innervated. These characteristics together with the unique expression 
of Myosin Heavy Chain-EO (MyHC13) (Schiaffino and Reggiani 2011), sets them apart 
from all other skeletal muscles, as a distinctive group of highly specialized muscles (Spencer 
and Porter 1988). The orbicularis oculi muscles on the other hand, comprise the sphincter 
muscles of the eyelids; they are classified as facial muscles and functionally antagonize the 
levator palpebrae superior muscles which are accessory extraocular muscles (Porter, Rafael 
et al. 1998). The orbicularis oculi muscles can be subdivided into orbital, palpebral and 
lacrimal portions. The orbital portion firmly closes the eyelids and is controlled by voluntary 
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action; the palpebral portion closes the eyelids gently in involuntary or reflex blinking; the 
palpebral portion can be further divided into pretarsal, preseptal portion, and ciliary. The 
lacrimal portion compresses the lacrimal sac, which receives tears from the lacrimal ducts 
and conveys them into the nasolacrimal duct (Gray and Lewis 1918). The orbicularis oculi 
muscles derive from the mesenchyme in the second pharyngeal arch (Moore, Persaud et al. 
2015) and are innervated by the VII cranial nerve (Ouattara, Vacher et al. 2004).  
Weakness of the orbicularis oculi muscles is often apparent in neuromuscular 
disorders affecting the neuromuscular junction (Walsh, Newman et al. 2008). Similar to 
extraocular muscles, they are also one of the first targets of mitochondrial myopathies and 
Myasthenia gravis, resulting in weakness of eyelid closure usually and ptosis (Walsh, 
Newman et al. 2008). Facial weakness and ptosis have also been described in patients with 
recessive RYR1 mutations (the gene encoding the RyR1) (Taylor, Lachlan et al. 2012), 
affected by Multi Minicore Disease, Congenital Fiber Type Disproportion and 
Centronuclear Disease (Jungbluth, Zhou et al. 2005, Treves, Jungbluth et al. 2008, Clarke, 
Waddell et al. 2010, Wilmshurst, Lillis et al. 2010). On the other hand, EOM are spared in 
aging, Duchenne muscular dystrophy and Congenital muscular dystrophy when all other 
skeletal muscles are affected (Kaminski, al-Hakim et al. 1992, Khurana, Prendergast et al. 
1995, Kallestad, Hebert et al. 2011). Weakness of the facial musculature caused by any 
disease is almost certainly accompanied by weakness of the orbicularis oculi muscles as 
well (Walsh, Newman et al. 2008). The present investigation was undertaken in order to 
identify similarities and differences in ECC and calcium homeostasis in human extraocular 
muscles, orbicularis oculi and quadriceps, in order to identify factors that might contribute 
to the selective involvement in different neuromuscular disorders. The results of the present 
investigation show that that the ECC machinery and calcium regulation of human 
orbicularis oculi are more similar to those of quadriceps than of EOM; on the other hand 
orbicularis oculi and EOM are similar in that they both express high levels of utrophin, 
while quadriceps express dystrophin. This findings explains the sparing of facial and EOM 
muscles in Duchenne patients; since the ECC machinery between orbicularis oculi and 
quadriceps appears to be similar, our study points to a potential use of autologous facial 
muscle-derived satellite cells for muscle re-implantation in patients with muscular 
dystrophy.  
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MATERIALS AND METHODS 
Human muscle cell cultures 
Primary muscle cell cultures were established from fragments of quadriceps muscles 
obtained from biopsies of healthy donors (6 donors), orbicularis oculi muscle samples from 
patients undergoing eyelid cosmetic procedure or blepharoplasty (5 donors) and extraocular 
muscle samples obtained from patients undergoing squint corrective surgery (4 donors), as 
described previously (Censier, Urwyler et al. 1998, Ducreux, Zorzato et al. 2004). Laminin-
coated 0.17 mm thick glass coverslips were used for calcium imaging; briefly cells were 
plated on the coated glass coverslips and allowed to grow in growth medium (Skeletal 
Muscle Cell Growth Medium, Promo Cell Cat N° C-23080) until cells were approximately 
80% confluent at which point they were induced to differentiate into myotubes by switching 
the medium to differentiation medium (Skeletal Muscle Cell Differentiation medium, Promo 
Cell, Cat N° C-23061) for 7–14 days. This research was carried out in accordance with the 
Declaration of Helsinki (2013) of the World Medical Association, and was approved by the 
Ethikkommission beider Basel (permit N° EK64/12); all subjects gave written informed 
consent to carry out this work. 
Calcium measurements 
Fura-2 (Calbiochem) or fluo-4 (Life Technologies, Ltd) at final concentrations of 5 
µM were used to load myotubes for 30 min at 37°C, after which the coverslips were 
mounted onto a 37° C thermostatically controlled chamber that was continuously perfused 
with Krebs–Ringer medium; individual cells were stimulated by means of a 12- or 8-way 
100 mm diameter quartz micromanifold computer-controlled microperfuser (ALA Scientific 
Instruments, Westbury, NY, USA), as described previously (Ducreux, Zorzato et al. 2004).  
The fluorescent ratiometric Ca2+ indicator fura-2 was used for monitoring the global 
changes in the intracellular Ca2+ concentration. Online measurements were recorded using a 
fluorescent Axiovert S100 TV inverted microscope (Carl Zeiss GmbH, Jena, Germany) 
equipped with a 20× water-immersion FLUAR objective (0.17 N.A.) and filters (BP 
340/380, FT 425, BP 500/530) attached to a Cascade 128+ CCD camera Average pixel 
value for each cell was measured at excitation wavelengths of 340 nm and 380 nm as 
previously described (Censier, Urwyler et al. 1998, Ducreux, Zorzato et al. 2004). Fura-2 
fluorescent ratio signals were converted into [Ca2+] using the curve generated using the fura-
2 Ca2+ imaging calibration kit from Molecular Probes (Invitrogen) following the 
manufacturer’s instructions and as previously described (Vukcevic, Zorzato et al. 2013). The 
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dynamics of [Ca2+] influx were investigated by TIRF microscopy using the fast Ca2+ 
indicator Fluo-4 as previously described (Treves, Vukcevic et al. 2011). Myotubes were pre-
treated with 50 µM ryanodine (Calbiochem) in order to block Ca2+ release through the RyR1 
receptor and excitation coupled Ca2+ entry (ECCE) was stimulated by the application of 60 
mM KCl. Online fluorescence images were acquired using an inverted Nikon TE2000 TIRF 
microscope equipped with an oil immersion CFI Plan Apochromat 60× TIRF objective (1.49 
N.A.) and an electron multiplier Hamamatsu CCD camera C9100–13.  Metamorph imaging 
software from Molecular Devices was used for analysis of the fluorescence changes. 
Quantitative Real-time PCR 
Total RNA was extracted from muscle biopsies using Trizol (Invitrogen) and 
following the manufacturer’s instructions. RNA was first treated with deoxyribonuclease I 
(Invitrogen) and then 1000 ng were reverse transcribed using the high-capacity cDNA 
reverse transcription kit (Applied Biosystems). cDNA was amplified by quantitative real-
time PCR using SYBR Green technology (Fast SYBR Green Master Mix, Applied 
Biosystems) as previously described (Rokach, Ullrich et al. 2013). The sequences of the 
primers used for gene amplification and quantification is given in Supplementary Table 1.  
qPCR was performed on a 7500 Fast Real-Time PCR machine from Applied Biosystems 
using the 7500 software v2.3. Running method for qPCR was including a standard protocol 
consisted of holding stage at 50°C for 20 seconds and a denaturing step at 95°C for 10 
minutes, followed by 40 cycles of denaturing at 95°C for 15 seconds and an extension step 
at 60°C for 1 min. Gene expression was normalized to expression ACTN2, which is present 
in all muscle fiber types. Results are expressed as fold change compared to expression of the 
gene in quadriceps muscles.  
Immunofluorescence 
Differentiated human myotubes grown on a glass coverslip coated with laminin 
were fixed with 4% paraformaldehyde (made in Phosphate Buffered Saline, PBS), 
permeabilized with 1% Triton in PBS for 20 min and processed as previously described 
(Treves, Vukcevic et al. 2011). The following antibodies were used: mouse anti-RyR1 
(Thermo Scientific; MA3-925), goat anti-Cav1.1 (Santa Cruz; sc-8160), rabbit anti-Cav1.2 
(Santa Cruz, sc-25686), AlexaFluor 488 conjugated-chicken anti-rabbit, AlexaFluor 555 
conjugated-donkey anti-goat IgG (Life Technologies, Ltd) and AlexaFluor 647 conjugated-
goat anti-mouse IgG (Life Technologies, Ltd). Cells were stained with 4’,6-diamidino-2-
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phenylindole (DAPI) (Life Technologies, Ltd) to visualize nuclei and observed using a 
Nikon A1R confocal microscope with a CFI Apo TIRF 100X (1.49 N.A.) objective.  
Electrophoresis and Immunoblotting  
The total sarcoplasmic reticulum fraction was isolated from flash frozen muscle 
samples (human orbicularis oculi, EOM, quadriceps muscles and mouse heart) as previously 
described (Anderson, Treves et al. 2003) and stored in liquid nitrogen. The protein 
concentration was determined using the Protein Assay Kit II (Bio-Rad Laboratories) and 
BSA as a standard. SDS-PAGE, protein transfer on to nitrocellulose membranes and 
immunostaining were performed as previously described (Anderson, Treves et al. 2003). 
The following primary antibodies were used: mouse anti-RyR1 (Thermo Scientific, MA3-
925), goat anti-Cav1.1 (Santa Cruz sc-8160), rabbit anti-Cav1.2 (Santa Cruz, sc-25686) 
rabbit anti-calsequestrin-1 (Sigma, C-0743), goat anti-SERCA1 (Santa Cruz, sc-8093) and 
mouse anti-sarcalumenin (Thermo Scientific, MA3-932) anti-dystrophin (Abcam, ab-7164), 
anti-utrophin (Santa Cruz, sc-15377) and mouse anti-myosin heavy chain (Millipore, 05-
716). Secondary peroxidase conjugates were protein G-peroxidase (Sigma, P8170) and 
peroxidase-conjugated goat anti-mouse IgG) (Sigma, A2304). The immunopositive bands 
were visualized by chemiluminescence using the Super Signal West Dura kit (Thermo 
Scientific) or the Chemiluminescence kit from Roche. 
For Myosin Heavy Chain, gels were performed as described by Talmadge and Roy	
(Talmadge and Roy 1993) except that 30 µg total protein extracts were separated and the 
final acrylamide concentration was 6.5%. Gels were stained with Coomassie Brilliant Blue.  
Statistical analysis  
Statistical analysis was performed using the Student’s t-test for two populations. 
Values were considered significant when P<0.05. When more than two groups were 
compared, analysis was performed by the ANOVA test followed by the Bonferroni post hoc 
test, using the GraphPad Prism 4.0 software. The Origin Pro 8.6 software was used for 
generating dose-response curves. 
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RESULTS 
Gene and protein expression levels in human orbicularis oculi, EOM and quadriceps 
muscles 
The expression levels of the major gene products involved in skeletal ECC is 
shown in figure 1A; the values obtained from orbicularis oculi were compared to those 
obtained from quadriceps of healthy donors. The latter muscles were used as reference and 
the expression level of different genes therein was set to 1. The results show the mean 
(±SEM) expression level of genes from five pooled biopsy samples normalized to ACTN2. 
The expression of RYR1 and SERCA1 transcripts was slightly elevated (approximately 2 
fold; *P<0.05 Student’s t test), as was that of RYR3 and CACNA1C (5 and 10 fold, 
respectively; ***P<0.0001 Student’s t test) while CACNA1S expression was similar in 
orbicularis oculi and quadriceps muscles. Interesting, the expression levels of UTRN and 
DMD showed  ~ a 13 and 16-fold increase, respectively compared to quadriceps muscles 
(***P<0.0001 Student’s t test). Although it was reported that MYH13 isoform is exclusively 
expressed in EOM (Wieczorek, Periasamy et al. 1985), we also found that it is expressed in 
orbicularis oculi (Fig. 1B). JP45 levels remained unchanged.  
Total sarcoplasmic reticulum fractions were prepared and probed with antibodies 
against the major skeletal ECC proteins as well as Cav1.2; the intensities of the 
immunoreactive bands were normalized to sarcalumenin content and are expressed as % 
expression of that of quadriceps muscles. Surprisingly, at the protein level the content of 
RyR1, Cav1.1, SERCA1, and CASQ1 were not changed between orbicularis oculi and 
quadriceps (Fig. 1C). We chose to normalize to SRL content and not to SERCA1 or 
calsequestrin 1, since by qPCR both SERCA1 and CSQ1 transcripts were significantly 
increased in orbicularis oculi. Cav1.2, the cardiac isoform of the DHPR could not be 
detected in western blots of orbicularis oculi and quadriceps, but it is clearly present in 
human EOM and mouse heart which served as positive control (Fig. 1D). Utrophin was 
highly expressed in both EOM and orbicularis oculi but less so in quadriceps (4-fold in OO 
vs QU *P< 0.05), while the opposite was true for dystrophin (OO expressed approximately 
50% compared to QU *P<0.05) (Fig. 1E).  
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Ca2+ homeostasis in human myotubes derived from orbicularis oculi, EOM and 
quadriceps 
Since in a previous study we showed that primary cultures of myotubes explanted 
from human EOM muscle biopsies had different Ca2+ handling properties, in the next series 
of experiments we compared Ca2+ homeostasis in myotubes derived from the three types of 
muscles.	 In the first set of experiments cells were perfused with Krebs-Ringer containing 
100 µM La3+ to prevent influx of extracellular Ca2+ and to ensure that the measurements 
represent skeletal ECC. As shown the KCl-induced Ca2+ release was not different in 
orbicularis oculi -derived myotubes compared to quadriceps-derived myotubes (Fig. 2A). 
Similar results were reported for EOM (Sekulic-Jablanovic, Palmowski-Wolfe et al. 2015) 
and the curves are not shown in the figure for simplicity. The 4-cmc induced Ca2+ release 
curve was also similar between orbicularis oculi - and quadriceps-derived myotubes (Fig. 
2B). There were small differences in the resting  [Ca2+]i in the three populations of myotubes 
while the size of the intracellular Ca2+ stores of orbicularis oculi -derived myotubes were 
similar to those of quadriceps -derived myotubes, but significantly lower than those of  
EOM-derived myotubes (Fig. 2C and D; Student’s t test ***P<0.0001).	
We next investigated excitation-coupled Ca2+ entry (ECCE), the process by which 
membrane depolarisation activates Ca2+ influx through the dyhydropiridine receptor	
(Bannister, Pessah et al. 2009). The top panels of figure 3A show pseudocoloured fluo-4 
fluorescent changes in a representative myotube pre-treated with 50 µM ryanodine and 
stimulated with 60 mM KCl; the pre-treatment with high concentrations of ryanodine is 
necessary to block Ca2+ release through RyR, ensuring that the change in fluo-4 fluorescence 
is not due to Ca2+ release from the SR, but rather from Ca2+ influx through the 
dyhydropiridine receptor. Figure 3B shows a representative Ca2+ influx trace initiated by the 
application of 60 mM KCl in orbicularis oculi -derived myotubes (____), quadriceps-
derived myotubes (-.-.-.) and EOM-derived myotubes (……). Figure 3C summarizes the 
results confirming that ECCE in orbicularis oculi myotubes is not significantly different 
from quadriceps myotubes, but almost 3 fold lower compared to EOM derived myotubes. 
The difference in Ca2+ influx between EOM and orbicularis oculi muscles most 
likely reflects the differential expression of Cav isoforms in these groups of muscles. Figure 
4 (top panels) shows the subcellular distribution of Cav1.1 and RyR1 in orbicularis oculi 
myotubes; as seen the distribution of Cav1.1 (panel A, green) and RyR1 (panel B, red) is 
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punctuated and unstructured, within an intracellular membrane compartment. Though they 
lack a mature organization, RyR1 and Cav1.1 co-localize within the myotube (Fig. 4C). A 
similar subcellular punctuated distribution of Cav1.1 (Fig. 4E) and RyR1 (Fig. 4F) is found 
in EOM myotubes however, there are major differences in the expression and distribution of 
Cav1.2, that is, this isoform is exclusively distributed on the plasma membrane of EOM-
derived myotubes (Fig. 4H) and could not be detected in orbicularis oculi myotubes (Fig. 
4D). 
DISCUSSION 
In the present study we investigated the biochemical and physiological 
characteristics of orbicularis oculi muscles a group of facial muscles that are selectively 
spared or involved in different neuromuscular disorders. As far as the expression of proteins 
involved in ECC is concerned, it appears that orbicularis oculi muscles are closer to 
quadriceps than to EOM. Indeed, the content of skeletal muscle sarcoplasmic reticulum 
proteins was similar between quadriceps and orbicularis oculi muscles and differed from 
that of EOM, as only the latter express proteins characteristic of both cardiac and skeletal 
muscle ECC (Sekulic-Jablanovic, Palmowski-Wolfe et al. 2015). Surprisingly however, the 
expression of transcripts did not always match the actual protein content, highlighting the 
importance of validating arrays or qPCR experiments whenever possible. This was 
particularly relevant for the difference between the expression of Cav1.2 and dystrophin 
whose transcripts were increased >8-10 fold in orbicularis oculi, but at the protein level they 
were barely detectable. The reason for this discrepancy is at present unclear, but agreement 
between mRNA and protein content occurs only approximately 40% of the time and is 
influenced by different factors, including mRNA and protein stability, presence of 
microRNAs, posttranscriptional modifications, with the key role in determining protein 
abundance being played at the level of translation (Tian, Stepaniants et al. 2004, Vogel, 
Abreu Rde et al. 2010, Schwanhausser, Busse et al. 2011). A limited overlap in genomic and 
proteomic data was also reported by Khanna et al. while profiling EOM and leg muscles 
(Khanna, Merriam et al. 2003). 
From a point of view of calcium homeostasis it appears that orbicularis oculi 
muscles are closer to quadriceps than to EOM, since the Ca2+-release dose response curves, 
the resting [Ca2+], and ionomycin/thapsigargin sensitive intracellular stores, in myotubes 
derived from the two muscle types were functionally undistinguishable and were clearly 
different from EOM-derived myotubes. The latter have significantly larger 
ionomycin/thapsigargin sensitive intracellular stores, express Cav1.2 and exhibit a 3- fold 
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larger ECCE.  One of the physiological characteristics of EOM muscles is that they are 
fatigue resistant (Fuchs and Binder 1983) and this may be functionally related to the high 
levels of expression of Cav1.2 and consequent large Ca2+ influx. The Ca2+ influx may be 
used as a means (i) to activate ECC more rapidly by enhancing Ca2+ induced Ca2+ release, or 
(ii) to rapidly replenish intracellular stores. ECCE is less pronounced in myotubes derived 
from other skeletal muscles, most likely because they lack the cardiac isoform of the alfa1 
DHPR subunit.  
Though orbicularis oculi express a typical skeletal muscle ECC, they also show 
similarities with EOM in that they express MyHC13 and high levels of RYR3. In humans, 
Orbicularis oculi are composed of 90% type II fibers and 10% type I fibers (Wirtschafter, 
Lander et al. 1994, Campbell, Williams et al. 1999) but our results show that they also 
express MyH13. In a study on levator palpebrae and retractor bulbi muscles from different 
species, it was shown that the latter muscles also express MyHC13 and that this is probably 
responsible for their rapid contracture times (<10 msec), in fact limb muscles do not express 
the superfast myosin isoforms and their contracture time is about 5 times longer	(Lucas and 
Hoh 1997). As far as RYR3 expression is concerned, our results are enigmatic since in 
general RYR3 transcripts are expressed at low levels, if at all, in adult skeletal muscle 
(Martin, Chapman et al. 1998) and the role of RyR3 is unclear. RYR3KO mice are viable, 
their muscles show no obvious physiological differences compared to their wild type 
littermates including no changes in electrically induced Ca2+ release and contractile 
properties of adult muscle fibers, though skeletal muscles from neonatal RYR3 KO mice 
show decreased tension development (Takeshima, Ikemoto et al. 1996). Although for the 
time being the function of RyR3s is speculative, it is possible that these channels act as 
amplifiers of the Ca2+ signals; compatibly, RYR3KO mice were reported to have a mild 
cognitive impairment when tested on a water maize (Balschun, Wolfer et al. 1999), but 
retrospectively, this may have also been related to a visual impairment. Studies aimed at 
understanding the role of RyR3 in EOM are currently under way. 
Our results concerning the expression of utrophin are interesting and most likely 
explain why in patients with Duchenne muscular dystrophy ocular and facial muscles are 
spared. Furthermore the observation that EOM are spared in Duchenne muscular dystrophy 
even though they exhibit a large Ca2+ influx, provides strong evidence that controlled Ca2+ 
influx per se, is not deleterious to skeletal muscles as recently proposed (Millay, 
Goonasekera et al. 2009), but is actually a physiological mechanism used by some skeletal 
muscles.  
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Utrophin and dystrophin share considerable sequence and structural homology	
(Tinsley, Blake et al. 1992, Winder, Gibson et al. 1995) and utrophin can associate with the 
dystrophin associated complex serving as a link between actin and the extracellular matrix	
(Matsumura, Ervasti et al. 1992). In mdx mice it is believed that utrophin compensates for 
the lack of dystrophin (Wakefield, Tinsley et al. 2000). Based on our results and on the fact 
that mdx knocked out also for utrophin show EOM involvement (Baker, Kearney et al. 
2006), it appears that utrophin can functionally compensate in vivo for the lack of 
dystrophin, supporting the current strategies aimed at modulating utrophin expression in the 
therapy for Duchenne muscular dystrophy	 (Perkins and Davies 2002, Chakkalakal, 
Thompson et al. 2005, Guiraud, Squire et al. 2015). 
Taken together these studies show that subspecialization of skeletal muscles occurs 
through multiple factors; while it is true that muscle innervation plays a prominent role, the 
distribution of a specific muscle within a niche devoted to a precise physiological function is 
also important. Indeed the term muscle allotype was proposed to describe the different 
capacities of myogenic cells of different lineages to express a different subset of myofibrillar 
genes. Since EOM, Orbicularis oculi and levator palpebrae (and the retractor bulbi which is 
present in some mammals but not in humans) are derived from cells from different lineage 
than those giving rise to limb muscles, their myogenic precursors must be programmed to 
express different subsets of proteins. The present study substantiates the validity of the 
muscle allotype hypothesis since we show that satellite cells derived from different muscles 
are primed and will follow the developmental characteristics of their muscle of origin, a 
property that can be exploited in laboratories devoted to tissue engineering.    
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FIGURE LEGENDS 
Figure 1: Expression of major excitation-contraction coupling transcripts and proteins 
in human orbicularis oculi muscle biopsies. (A) Gene expression was carried out by qPCR 
as described in the Materials and Methods section. Each reaction was carried out in 
triplicate, in pooled muscle samples from 5 biopsies from different individuals. Expression 
levels were normalized to ACTN2 expression. Results are expressed as mean fold change of 
transcripts in orbicularis oculi compared to quadriceps, the latter was set as 1. Results were 
analyzed using the Student’s t-test (*p<0.05; ***P<0.0001). (B) MYH13 gene expression 
was carried out by qPCR as described in Materials and Methods section. Each reaction was 
carried out in triplicate, in pooled muscle samples from 5 biopsies from different 
individuals. Expression levels were normalized to ACTN2 expression. Results are expressed 
as mean fold change of transcripts in orbicularis oculi compared to quadriceps, the latter 
were set as 1. Results were analyzed using the Student’s t-test (***p<0.0001). Insert shows 
MyHC protein expression in EOM and orbicularis oculi muscle homogenates; 10 and 30 µg 
protein were loaded per lane, respectively. Gels and conditions were as described in the 
Materials and Methods section. (C) Western blot analysis of total sarcoplasmic reticulum 
proteins in human orbicularis oculi and quadriceps muscles. Thirty micrograms of protein 
were loaded per lane and separated on 6% SDS-PAGE or 10% SDS-PAGE. Blots were 
probed with the indicated antibodies. Bar histograms represent the mean (± SEM) band 
intensity normalized to sarcalumenin content. (D) Western blot of human quadriceps, EOM, 
orbicularis oculi and mouse heart (positive control) total sarcoplasmic reticulum proteins, 
probed with Cav1.2 antibody. Thirty micrograms of protein was loaded per lane and 
separated on 6% SDS-PAGE. (E) Western blot of total muscle extracts; 30 µg of protein 
were loaded per lane, separated on 6% SDS-PAGE and probed with anti-utrophin (top) and 
anti-dystrophin (bottom) antibodies. Bar histograms represent the mean (± SEM) band 
intensity normalized to MyHC content (* P<0.05 Student’s t test). 
Figure 2: Calcium homeostasis of orbicularis oculi-derived myotubes compared to 
lquadriceps and EOM muscle-derived myotubes. Myotubes were loaded with 5 µM fura-
2 and perfused with Krebs–Ringer medium containing 2 mM CaCl2. For KCl- and 4-cmc 
induced Ca2+ release, individual cells were perfused with Krebs–Ringer plus 100 µM La3+ 
and the indicated concentration of agonist was applied using a microperfusion system. (A) 
KCl dose response curve (B) 4-cmc dose response curve- Orbicularis oculi-derived 
myotubes filled circles, continuous line and quadriceps derived myotubes empty circles, 
dotted line. Curves show the changes in peak calcium, expressed as [Ca2+] in nM. Each point 
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represents the mean (±SEM) of minimum 5-12 different cells. (C) Mean (±SEM) resting 
[Ca2+]. *P<0.05; **P<0.001. (D) Total amount of Ca2+ in the sarcoplasmic reticulum. The 
total amount of rapidly releasable Ca2+ in the stores was determined by calculating the area 
under the curve of the transient induced by the application of 1 µM ionomycin, plus 1 µM 
thapsigargin in Krebs-Ringer containing 0.5 mM EGTA. Values represent the mean (± 
SEM) calculated area under the curve. Student’s t test ***p<0.0001. For quadriceps-derived 
myotubes cells from 6 donors were measured, for orbicularis oculi-derived myotubes cells 
from 5 donors and for EOM-derived myotubes cells from 4 donors. 
Figure 3: Depolarization-induced Ca2+ influx in orbicularis oculi, EOM and quadriceps 
derived myotubes. Ca2+ influx induced by the addition of 60 mM KCl was monitored using 
a TIRF microscope in myotubes pre-incubated with 50 µM ryanodine to block RyR1 
mediated Ca2+ release and loaded with 5 µM fluo-4. (A) Top panels, pseudocolored 
ratiometric images (peak fluorescence after addition of KCl/resting fluorescence) of fluo-4 
fluorescence changes after application of 60 KCl to orbicularis oculi-derived myotubes (A1 
EpiSRIC image, A2-5 pseudocolored ratiometric images at 2, 5, 11 and 20 sec after the 
addition of KCl). (B) Representative excitation-coupled Ca2+ entry (ECCE) trace showing 
changes in fluo-4 fluorescence in a EOM-derived myotube (. . . . .), quadriceps derived 
myotube (._._.) and orbicularis oculi (______). (C) Mean (±SEM) peak increase of fluo-4 
fluorescence induced by 60 mM KCl in human orbicularis oculi-derived myotubes (white 
bar), EOM derived-myotubes (gray bar) compared quadriceps-derived myotubes (black bar). 
Experiments were performed on cells obtained from at least 4 different biopsies and results 
were averaged. Statistical analysis was performed using the ANOVA test; *** P<0.0001.  
Figure 4: Cellular localization of RyR1 and Cav1.1 in differentiated orbicularis oculi -
derived myotubes. Human myotubes were visualized with a Nikon A1R confocal 
microscope equipped with a CFI Apo TIRF 100X objective (1.49 N.A.) and stained as 
described in the Materials and Methods section. Top panels orbicularis oculi, bottom panels 
EOM. Panels A and E anti-Cav1.1 (green), B and F anti-RyR1 (red), C and G, merged 
image of anti-RyR1, anti-Cav1.1 and DAPI (blue); orange pixels show co-localization 
between RyR1 and Cav1.1. Panels D and H, anti-Cav1.2 (green). Bar indicates 20 µm. 
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2.2 Ryanodine receptors 1 and 3 – functional consequences of the 
mutations in human RYR1 or the absence of RYR3 in mice 
 
2.2.1 Introduction  
 
Ryanodine receptor 1 plays a crucial role in the process of the excitation contraction 
coupling in skeletal muscle. According to our study on human EOM, the expression of this 
receptor is decreased in EOM compared to that of human leg muscles. We were intrigued by 
this finding, as EOMs belong to the group of specialized skeletal muscles. Previous 
investigations in patients with recessive mutations in RYR1 where one allele carries 
missense mutation and other stop mutation, indicated the presence of the weakness of the 
EOM muscles, known as ophthalmoplegia. In those patients muscle biopsies show a 
decrease in the content of the RyR1 protein	 [171]. For the purpose of investigating the 
effects of mutations found in these patients, we subcloned human RYR1 cDNA into a 
mammalian bicistronic vector and used it for the insertion of specific mutations.  
 
As mentioned in the previous sections RyR3 does not directly participate in ECC, as mature 
muscles express either very little or no RyR3 and still show normal excitation-contraction 
coupling and RYR3 KO mice show no muscle impairment, no changes in muscle 
development and no alteration of other studied physiological parameters, except for a 
reported cognitive impairment [172]. 
 
In light of our findings on the low levels of RyR1 expression in EOM together with the low 
levels of skeletal alfa 1s of the DHPR and the presence of the cardiac alfa 1c isoform, we 
were prompted to investigate the EOM function in the RYR3 KO mice in fact we 
hypothesize that this animal model has an impairment of EOM function and this was not 
investigated in previous studies. 
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2.2.2 Subcloning and introducing the mutations in human RYR1  
 
In order to better understand the consequences of RYR1 mutations, the human RYR1 
mRNA from healthy donor was used as template for cDNA synthesis which was further 
subcloned and finally used to establish a stably transfected cell culture of HEK 293 
expressing RyR1. Furthermore RyR1-vector construct was used for introducing specific 
mutations found in patients. 
Assembling the RyR1-vector construct 
 
RYR1 cDNA was synthesized using mRNA isolated from human skeletal muscle as a 
template (transcript variant 2, NCBI Reference Sequence: NM_001042723.1). When 
compared with the NCBI nucleotide database entry, six nucleotide changes that do not affect 
the amino acid sequence of the RyR1 protein were detected by sequencing. These were: 
c.724A>G, c.1207T>C, c.1798G>A, c.2416 C>T, c.3073G>A and c.9187C>T. 
 
The full length RYR1 cDNA was assembled through a series of subcloning steps in which 
fragments of different sizes (from 600bp-2629bp) were amplified by insertion in the pBSK 
(-) vector, followed by ligation and joining one insert at a time to obtain the full length 
construct (Fig. 17). Each fragment was checked by direct sequencing before being ligated to 
the next clone. The final complete RYR1 cDNA sequence inserted in pBSK(-) was 
confirmed to be from the first ATG start codon to the stop codon (positions 131-15234 of  
the RYR1 sequence). The full length RYR1 cDNA was inserted in pIRES-DsRed vector in 
order to achieve transfection and expression in mammalian cells.  
 
 
	
 
Figure 17: RYR1 cDNA subcloning scheme. In the scheme are represented the restriction sites 
chosen to break the total cDNA into smaller clones to be used in a second phase of getting the full 
length cDNA. 
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3`untranslated region of RYR1 was first inserted in pBSK(-) vector through digestion with 
HindIII/XbaI and this new construct was digested with SacI/SalI in order to transfer 3`UTR 
in pIRES-DsRed vector. In the final step, RYR1 insert was cut out from the pBSK(-) with 
SpeI/XbaI and inserted in XbaI digested 3`UTR in pIRES-DsRed construct (Fig. 18). 
 
	
Figure 18: Final assembling of RYR1 insert with its 3`UTR fragment in pIRES-DsRed 
vector. 
	
 
Stable transfection  
 
HEK293 were stably transfected with the RYR1 cDNA construct outlined above in order to 
ascertain that the appropriate recombinant protein was obtained. HEK293 cells were chosen 
for transfection because they do not express endogenous RyR1. The stably transfected 
clones D2 and A5 were observed for the DsRed fluorescence and as shown in figure 19, all 
the cells were positive for the DsRed signal. Transfected cells were collected and the 
microsomal fraction was prepared. As can be seen in figure 20, a high molecular weight 
immunoreactive band was present in the microsomes of transfected cells. The size of the 
immunoreactive band matched that of RyR1 present in rabbit terminal cisternae.  
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Figure 19. DsRed fluorescence present in the stably transfected HEK293 clones. Cells 
from clones A5 and D2 grown on laminin coated glass coverslips and observed for the DsRed 
fluorescence. 
 
 
 
 
                                
 
 
Figure 20: Western blot of microsomes from transfected Hek293 cells. (clones A5 and D2) 40µg 
and 80 µg protein were loaded per lane for each clone and separated on a 5% SDS-PAG. The blot was 
incubated with 0.5 µg/ml mAb 34C anti-RyR1 followed by anti–mouse peroxidase and the reaction 
was visualized by chemiluminescence. 	
The lanes on the left (positive control) were loaded with 4 and 2 µg rabbit skeletal muscle terminal 
cisternae and the arrow indicates the immunoreactive band corresponding to the RyR1 protomer.
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Stably transfected cells from clone A5 were grown on a glass coverslip and fixed with 4% 
paraformaldehyde, permeabilized with 1% Triton in PBS for 20 min and stained with the 
mouse anti-RyR1 antibody. The staining was positive for the presence of the RyR1 protein in 
the cells as well as previously shown DsRed fluorescence (Fig. 21). 
 
 
 
Figure 21: Cellular localization of RyR1 and DsRed.  Merged image of cells stained with 
anti-RyR1 (green), nuclear counterstain DAPI (blue) and expressed DsRed protein fluorescence 
(red). Visualized with a Nikon A1R confocal microscope equipped with a CFI Apo TIRF 100X 
objective (1.49N.A.) 
 
 
Ca2+ measurments 
 
Clones were further tested for RyR1 function by monitoring calcium changes after 
stimulation with the RyR1 agonist 4-chloro-m-cresol (600µM) and caffeine (10mM). 
Positive clones were expanded and allowed to grow on glass coverslips; when enough cells 
were present, they were loaded with the ratiometric Ca2+ indicator fura-2 and changes in 
fluorescence were monitored. Figure 22 shows the results of a representative experiment. 
Traces A and B are showing that tranfected HEK293 respond to the addition of 10 mM 
caffeine and 600µM 4-cmc respectively. Panel C shows the pseudo colored ratiometric 
changes in fura-2 fluorescence elicited by the addition of 600µM 4-cmc in the latter cells. 
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Figure 22: HEK293 cells transfected with human RYR1 respond to caffeine and 4-cmc 
addition. Cells from selected clones were grown on glass coverslips, loaded with 10µM fura-2 Ca2+ 
indicator and stimulated with (A) 10 mM caffeine and (B) 600µM 4-cmc in Krebs Ringer. (C) 
photographs of cells B showing 3 time points during caffeine stimulation. The trace shown in panel 
B was obtained from the cell indicated by the arrow in trace C.  
 
 
After the stability of the expression of RyR1 in previously described clones was confirmed, 
the next step was to introduce mutations into RyR1 receptor sequence and test for the 
functional and protein expression changes. A premature stop mutation similar to one found 
in patients c.2367C>A was introduced into RYR1 vector and using the electroporation 
protocol mutated cDNA was introduced into FDB. Briefly, cDNA from nucleotide 131 to 
2367 was amplified by PCR and subcloned into the pIRES-DsRed vector (Clontech) into 
which the 3`UTR sequence of RyR1 (from nucleotide 15235-15376) had previously been 
inserted. The following primers were used for RYR1TRUNC subcloning: F 5`- GACCT CGA 
GGT CGA CGG TAT CGA TAA-3` and R 5`-GGATC TAG AAC GCT GAG GTC CAG 
TCA G -3`. All sequences were verified by Sanger sequencing. 
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Mouse FDB were then electroporated with the wild type or truncated RYR1; after one week 
FDB fibers were isolated and proteins were probed for the presence of the ubiquitin as a 
signal for degradation. As can be seen in figure 23A the band with truncated RyR1 protein is 
heavily marked with anti-ubiquitin antibody (Millipore 04-363), while at the same time the 
mRNA levels of truncated RYR1 are highly increased compared to the control levels 
detected from the isolated FDB fibers of the other leg, indicating that electroporation was 
efficient (Fig. 23B), but the translated protein is being degraded. 
 
 
 
 
Figure 23: Increase in ubiquitination of the truncated RyR1 protein. (A) Western blot of 
the total homogenate from the isolated FDB fibers, from control leg and electroporated one, probed 
for anti-ubiquitin antibody and normalized to MyHC content. (B) Relative expression of truncated 
RYR1 in isolated transfected fibers compared to control fibers.  
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2.2.3 Extraocular muscle properties in RyR3 knockout mice 
 
Considering that we found RYR3 to be highly expressed in human EOM it was equally 
interesting to test RYR3 levels in mouse EOM. As can be seen in figure 23, the pattern of 
RYR1, CACNA1S, and CASQ2 expression was different in mouse EOM compared to human 
EOM, but the RYR3 transcript levels were similarly increased, up to 100 fold compared to 
FDB fibers. This led us to investigate the function of the extraocular muscles in the RYR3 
knockout mice.  
 
 
Figure 23: Expression of excitation-contraction coupling transcripts in human (A) and 
mouse (B) extraocular muscle biopsies. Gene expression was quantified by qPCR. Each 
reaction was carried out in triplicate, in pooled muscle samples from 4-5 biopsies from different 
individuals. Expression levels were normalized to ACTN2 expression. Results are expressed as mean 
fold change of transcripts in EOM compared to human quadriceps muscles and to mouse FDB fibers, 
the latter were set as 1. Results were analyzed using the Student’s t-test (***p<0.0001, **p<0.001, 
*p<0.01).  
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For the preliminary functional test, we chose to investigate the optokinetic reflex and 
measure visual acuity (clarity of vision), using the OptoMotry© system. Image stabilization 
is predominantly mediated by two types of oculomotor responses: the optokinetic reflex 
(OKR; also called optokinetic nystagmus or OKN) and the vestibulo-ocular reflex (VOR) 
The OKR is induced when the entire visual scene drifts across the retina, eliciting eye 
rotation in the same direction and at a velocity that minimizes the motion of the image on 
the retina. The VOR is an analogous response to head movement, with input coming from 
the vestibular system rather than the retina. Normally, the OKR and VOR work together to 
ensure image stabilization on the retina. Both the OKR and the VOR are controlled by 
subcortical circuits: the OKR is controlled by neurons in the retina, diencephalon and 
midbrain (the accessory optic system), pons, and dorsal medulla, and the VOR is controlled 
by neurons in the labyrinth of the inner ear, midbrain, pons, dorsal medulla, and cerebellum	
[173]. 
OptoMotry© is used for the rapid screening of functional vision using the opto-
kinetic  tracking/reflex  (OKT/R) response. Spatial frequency thresholds can be measured by 
systematically increasing the spatial frequency  of the grating at 100% contrast until animals 
no longer track. A contrast sensitivity function can be generated by identifying the minimum 
contrast that generates tracking, over a range of spatial frequencies. Single thresholds can be 
obtained in a few minutes in animals with no previous exposure to the task, and 
measurements can be repeated regularly.  Rodents stand on an elevated platform in the 
epicenter of an arena surrounded by computer monitors, and a camera images the behavior 
of the animal from above (Fig. 24). A cylinder comprised of a sine wave grating is drawn in 
3D coordinate space and rotates around the animal. Animals track the grating with reflexive 
head and neck movements (Fig. 25). A cursor placed on the forehead centers in real time the 
rotation of the cylinder at the animal’s viewing position, thereby “clamping” the effective 
spatial frequency of the grating [174]. 
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Figure 24: Schematic representation of the optomotor testing apparatus. (A) Side view. 
A mouse is placed on a platform positioned in the middle of an arena created by a quad-square of 
computer monitors. Sine wave gratings drawn on the screens are extended vertically with floor and 
ceiling mirrors. A video camera is used to monitor the animal’s behavior from above. (B) Top view. 
The mouse is surrounded by 360° of gratings and is allowed to move freely on the platform [174]. 
	
		
 
Figure 25: Virtual geometry and optomotor response. (A) A virtual cylinder is projected in 
3-D coordinate space on the monitors. The head of the mouse centers the rotation of the cylinder. (B) 
When the cylinder is rotated, the mouse tracks the drifting grating with head and neck movements. 
(C) A single-frame video camera image of a mouse tracking the cylinder grating. The four-line 
crosshair is positioned between the eyes of the mouse, and the coordinates are used to center the 
rotation of the cylinder	[174].  
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According to the results obtained after the first tests, there is a significant difference 
(***p<0.0001) in the visual acuity between RYR3 KO mice and WT, in terms of poorer 
vision of the knockout mice (Fig. 26).  
 
 
 
 
Figure 26: Visual acuity test of RYR3 KO mice. OptoMotry© detection system. Unit for 
visual acuity used is c/d (cycle/degree). 10 WT and 10 RYR3 KO mice tested in two independent 
measurements. Results were analyzed using the Student’s t-test ***p<0.0001.  
 
 
This was a good starting point for the measurements of EOM muscle function. The next 
planned experiment was a water maze test, where the visual impairment of RYR3 KO mice 
was further investigated. Visual acuity was tested using the visual platform version of the 
Morris Water maze. A round gray tank of 1,7m diameter filled to a height of 30cm with 
water at room temperature of 23 ± 1°C was used. The water was made opaque by the 
addition of non-toxic white paint. A video-camera fastened above the center of the pool 
recorded the swimming patterns of the mice, using a video tracking system (Ethovision™ 
XT11, Noldus Information Technology, Wageningen, Netherlands). The water surface was 
virtually divided into four quadrants. A white, round platform with a diameter of 10 cm, was 
placed in one quadrant, at a distance of 50 cm from the border and 2 cm above the water 
surface. 4 entry zones are marked outside the pool. The room was illuminated at an intensity 
of <150 Lux. Animals are transferred to the experimental room where they were given at 
least 72 h to acclimatize in 12 hourly light/dark cycles, the light being switched on at 6 am. 
Animals were provided with water and food ad libitum. On day 0, animals performed a 
habituation run, swimming for 60 sec in the water maze, after this period they were placed 
on the platform for 15 seconds. On day 1, animals were tested in a total of 4 trials with the 
platform at a fixed position, and varying each of the four entry zones. Test duration was 60 
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sec per run. If the animal did not find the platform after 60 sec, it was guided to it by hand 
and allowed to stay for 15 seconds.  On day 2, tests were repeated in a similar way as day 1, 
except that the platform was moved in the opposite quadrant. Parameters that were evaluated 
are: swimming velocity, total distance moved and time to reach the platform. There was no 
difference in swimming velocity between two strains, which was good indicator that the 
swimming capacity is unchanged in RYR3 KO and does not contribute to detected 
significantly higher time and distance to reach the platform (*p<0.05 and **p<0.005 
respectively)  (Fig. 27) .   
 
 
 	
Figure 27: Water maze results show visual impairment in RYR3 KO mice. The results are 
average per experimental group, per day. (A) Time spent to reach the platform; 10 mice were 
measured per strain and data from 4 different entry points are pooled. (B)  Distance to reach the 
platform; 10mice were measured per strain and data from 4 different entry points were pooled; 
*p<0.05, p*<0.005. 
 
Functional and biochemical testing of the isolated EOM fibers will be also part of the 
characterization of the RYR3 KO EOM phenotype. So far, I have isolated mouse WT EOM 
fibers, and by confocal microscopy showed that the Cav1.1, RyR1 proteins are distributed as 
in skeletal muscle fibers, but the cardiac isoform of DHPR Cav1.2 was found to be expressed 
and localized only on the membrane of the fiber, as previously found in human EOM 
derived myotubes (Fig. 28). 
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Figure 28: Cellular localization of RyR1, Cav1.1 and Cav1.2 in Mouse Extraocular 
muscle fiber. Samples were stained as previously described. Fiber was visualized with a Nikon 
A1R confocal microscope equipped with a CFI Apo TIRF 100X objective (1.49 N.A.).  
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CHAPTER 3: GENERAL CONCLUSION 
AND PERSPECTIVES 
 
 
 
 
 
Extraocular muscles are affected in individuals carrying recessive RYR1 mutations 
associated with multi-minicore disease, centronuclear myopathy and congenital fiber-type 
disproportion. Patients with severe congenital ophthalmoplegia and facial weakness in the 
setting of only mild skeletal myopathy harbor recessive mutations in RYR1, and are 
susceptible to malignant hyperthermia [175]. On the other hand, even within Malignant 
hyperthermia which is inherited in a dominant manner, there is a subgroup of patients which 
respond with masseter muscle rigidity - a severe, sustained contraction of the jaw muscle 
that may be observed after the administration of succinylcholine [176]. Our interest to 
investigate closer the properties of two muscle groups, the extraocular muscles and the facial 
orbicularis oculi muscles, led us to interesting discoveries. Finding that all major 
components of the skeletal excitation-contraction coupling in EOM were expressed at a 
lower levels was unexpected, as it is well known that EOM are one of the fastest muscles in 
the body. That was intriguing and made us question as to what additional signaling 
mechanism these muscles rely on. If it is not completely skeletal, might there be 
involvement of cardiac ECC components or some other factors? Indeed, the transcripts 
encoding RyR3, cardiac calsequestrin (CSQ2) and the α1 subunit of the cardiac 
dihydropyridine receptor were highly expressed in EOM compared to leg muscle. Cardiac 
DHPR was localized exclusively on the membrane of the EOM-derived myotubes and this 
was the first time that this isoform was detected in skeletal muscles. What is the exact role 
of this receptor in EOM muscles and how it contributes to the EOM phenotype is yet to be 
discovered. One explanation could be the increased depolarization induced Ca2+ influx in 
EOM that we reported, as it is practically abolished after adding of 50µM nifedipine to 
myotubes incubated in ryanodine. To what extent this effect can be attributed to the presence 
of cardiac DHPR cannot be resolved based on the experiments as nifedipine  blocks the L-
type calcium channels and is not specific for one isoform.  
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After discovering the high expression levels of RYR3 transcript, we were interested to know 
its role in EOM, since this isoform is highly expressed only during muscle development and 
in low levels in adult muscle tissues, such as the diaphragm and soleus. It seems that RyR3 
is not involved in ECC directly, as mice lacking this receptor show subtle changes in ECC 
and it seems that RyR1 successfully compensates for the absence of RyR3. This effect does 
not necessarily reflect the lack of RyR3 involvement in muscle, but might be the 
consequence of already low content of RyR3. In addition, when both receptors RyR1 and 
RyR3 are absent, functional and structural impairment is even more pronounced and this 
indicates that when RyR1 is absent, RyR3 does show some effect on myofibrilar 
organization. The reported reduction in the caffeine response of the RyR3 KO mice 
indicates that RyR3 could play a role in the CICR mechanism. Despite the fact that in RyR3 
KO mice ECC is normal, a reduced CICR response was present at high Ca2+ concentrations 
[116, 177]. According to the results we have so far on extraocular muscles from RyR3 KO 
mice, their optokinetic reflex seems to be impaired and the water maze test confirmed a 
visual impairment, since RyR3 KO mice failed to see the platform and this was translated in 
a longer time and distance to reach the platform, compared to WT mice. At the same time 
the velocity of the RyR3 KO mice was not different compared to WT, which excludes the 
possibility that the lower values in time and distance for RyR3 KO mice were due to general 
weaker muscle performance. Further testing would give some additional insights in the 
EOM muscle and muscle fiber function of these mice, as EOM are constantly active and 
require an exquisite calcium management. Further experiments on the RyR3 KO mice will 
be conducted and will be combined with the biochemical characterization and Ca2+ 
measurements on isolated EOM fibers.  
 
We have found that orbicularis oculi muscles exhibit more similarities with LM than with 
EOM in terms of protein and mRNA levels of skeletal ECC components. On a protein level, 
they seem not to express the cardiac isoform of the DHPR which was instead found to be 
present in EOM and this was supported by the unchanged ECCE compared to LM-derived 
myotubes. In Duchenne muscular dystrophy EOM are spared from pathology. The same is 
confirmed in mdx mice models where EOM are spared; while at the same time accessory 
EOM (retractor bulbi and LPS) are affected. We have found that human OO express higher 
levels of both dystrophin and utrophin. The next step would be to investigate the protein 
levels of utrophin and dystrophin in both OO and EOM and to see if there are any 
differences between them. 
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The second part of this thesis refers to RyR1 low protein levels found in patients with 
recessive RYR1 mutations. The human RYR1 cDNA was subcloned into a mammalian vector 
and used for the insertion of specific mutations found in patients. We thus discovered that 
introduction of a premature stop codon causes protein degradation. Further investigations 
will combine the insertion of several different mutations found in patients and following the 
functional effect on Ca2+ regulation, protein level expression and function in transfected 
cells. This investigation will hopefully clarify at least in part, what factors are involved in 
the pathophysiological mechanism of recessive RYR1 mutations leading to disease and 
impaired muscle function.				
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